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Cardiomyopathy accounts for 20-30% of acute heart failure cases in adult Africans. Several 
types of cardiomyopathy have been identified; this study focused primarily on the genetic 
causes of arrhythmogenic right ventricular cardiomyopathy (ARVC). Many genes are 
implicated in ARVC pathogenesis, but many remain to be identified. 
 
Methods and Results 
We investigated a South African family (ACM2) with autosomal dominant ARVC, for whom 
the genetic cause of disease was unknown. Extensive genetic analysis was previously 
performed using genome-wide linkage analysis, but no disease-causing genetic variant was 
identified.  We subsequently performed candidate gene screening of the phospholamban 
(PLN) gene, genome-wide copy number variant (CNV) analysis and whole exome sequencing 
to identify the causal genetic variant. 
The ACM2 family harboured no disease-causing PLN variants. However, on screening all 
cardiomyopathy cases in our registry (ARVC, dilated cardiomyopathy (DCM), hypertrophic 
cardiomyopathy and peripartum cardiomyopathy), we identified a known pathogenic PLN 
variant (c.25C>T; p.R9C) in a DCM family of European descent. This variant was reported in 
an American DCM family of European descent. Haplotype analysis revealed independent 
variant origins in these families. 
CNV analysis revealed no disease-causing variants in the ACM2 family. Whole exome 
sequencing of two affected ACM2 family members revealed 38 variants shared by these 
individuals. Variants were verified in family members and population controls by high 
resolution melt analysis and Sanger sequencing, and by bioinformatic analysis to predict 
variant pathogenicity. A novel N-cadherin (CDH2) c.686A>C (p.Q229P) variant segregated 
with ARVC in the ACM2 family and was bioinformatically predicted to be deleterious. An 
additional pathogenic CDH2 variant (c.1219G>A (p.D407N)) was identified in another 
individual with ARVC after screening 85 cases. These CDH2 variants were absent in normal 
population controls. Furthermore, alterations in Cdh2 are known to cause cardiomyopathy 
in rodent models. Taken together, these findings support the causal role of N-cadherin gene 
variants in human cardiomyopathy. 
 
Conclusion 
The detection of two different rare pathogenic variants in CDH2 in individuals with ARVC 
implicates this gene as a novel cause of the disease and a possible diagnostic and 
therapeutic target for cardiomyopathy. A known pathogenic variant in PLN was confirmed 
as a cause of DCM. 
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Cardiovascular disease (CVD) is the leading cause of death in all regions of the world except 
sub-Saharan Africa.1 CVD has a significant socioeconomic impact on society, causing 
immense suffering and loss of life as well as posing major economic challenges to 
developing countries, including costs to the healthcare systems and to the national 
economy. CVD, which manifests mainly as heart disease and stroke, is attributed to a 
number of risk factors, including high blood pressure, high plasma cholesterol, tobacco and 
alcohol use and low fruit and vegetable consumption.2 In sub-Saharan Africa, the major 
causes of heart failure (a major form of CVD) are hypertension, rheumatic heart disease and 
cardiomyopathy.3 Cardiomyopathy accounts for 20-30% of heart failure in adult African 
individuals and poses the greatest challenge among the CVD causative factors due to the 
difficulty of diagnosis, the high prevalence in resource-poor societies, and the associated 
high disease mortality.4 
1.1. Cardiomyopathy 
Cardiomyopathy is defined as a myocardial disease in which the heart muscle is structurally 
and functionally abnormal in the absence of coronary artery disease, valvular disease, 
hypertension, pericardial disease or congenital heart disease sufficient to cause the 
observed myocardial abnormality.5 Cardiomyopathies often result in progressive heart 
failure with significant morbidity and mortality, and may be primary (genetic, acquired or 
mixed) or secondary (inflammatory, infiltrative or toxic).6 Cardiomyopathies are classified 
into morphological and functional phenotypes, which may be familial or non-familial 
conditions.5 Various types of cardiomyopathy have been identified, including 
arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM), 
hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM) and left ventricular 
non-compaction cardiomyopathy.5 For the purpose of this study I will be focusing on ARVC 
which is the least understood form of cardiomyopathy in Africans. 
2 
 
1.1.1. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
ARVC is a rare inherited muscle disease characterised by replacement of the right 
ventricular myocardium by fibro-fatty tissue, causing electrical instability including 
ventricular arrhythmias in the early stages and later reduced contractility and heart failure 
(Figure 1.1).7-9 ARVC has been shown to have left-dominant and biventricular subtypes, and 
the broader term of “arrhythmogenic cardiomyopathy” has therefore been suggested.7 
 
                                      
Figure 1.1: Illustration of a heart with arrhythmogenic right ventricular cardiomyopathy. The 
right ventricular myocytes are replaced with fibro-fatty tissue leading to the arrhythmias 
characteristic of the disease (adapted from Hershberger et al. 2013)10 
 
Studies from Italy show that the prevalence of ARVC ranges from 1-2 per 5000 individuals 
and is responsible for 15-25% of cases of sudden cardiac death in patients <35 years;11 the 
prevalence in Africa remains to be determined. The first reported case of ARVC in South 
Africa was published by Munclinger and colleagues in 2000.12 The ARVC Registry of South 
Africa was established in 2004 by the Working Group on Registries of the Cardiac 
Arrhythmia Society of Southern Africa (CASSA). Preliminary information from this registry 
suggests that ARVC occurs in all segments of the population and that the clinical features, 
outcome and frequency of familial disease may be similar to observations in other parts of 
the world.13 
3 
The diagnosis of ARVC is made according to a set of Task Force Criteria, originally published 
in 1994 by McKenna and colleagues14, and modified in 2010 by Marcus and colleagues.15 
The criteria for the diagnosis of ARVC take into account structural, histological, arrhythmic, 
electrocardiography (ECG) and familial features of the disease (Table 1.1).15 Patients are 
classified as having definite, borderline or possible ARVC dependent on the number of major 
and minor criteria they fulfil.15 
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Table 1.1: ARVC Task Force Criteria (from Marcus et al. 2010)15 
MAJOR MINOR 
I. Global or regional dysfunction and structural alterations 
 
By 2D echocardiogram: 
Regional RV akinesia, dyskinesia, or aneurysm 
and 1 of the following (end diastole): 
PLAX RVOT ≥32 mm (corrected for body size [PLAX/BSA] ≥19 mm/m2) 
PSAX RVOT ≥36 mm (corrected for body size [PSAX/BSA] ≥21 mm/m2) 
or fractional area change ≤33% 
 
By MRI: 
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction 
and 1 of the following: 
Ratio of RV end-diastolic volume to BSA ≥110 ml/m2 (male) or ≥100 
ml/m2 (female) 
or RV ejection fraction ≤40% 
 
By RV angiography: 
Regional RV akinesia, dyskinesia, or aneurysm 
 
By 2D echocardiogram: 
Regional RV akinesia or dyskinesia 
and 1 of the following (end diastole): 
PLAX RVOT ≥29 to  <32 mm (corrected for body size [PLAX/BSA] ≥16 to 
<19 mm/m2) 
PSAX RVOT ≥32 to <36 mm (corrected for body size [PSAX/BSA] ≥18 to 
<21 mm/m2) 
or fractional area change >33% to ≤40% 
 
By MRI: 
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction 
and 1 of the following: 
Ratio of RV end-diastolic volume to BSA ≥100 to <110 ml/m2 (male) or 
≥90 to <100 ml/m2 (female) 
or RV ejection fraction >40% to ≤45% 
II. Tissue characterisation of wall 
 
Residual myocytes <60% by morphometric analysis (or <50% if 
estimated), with fibrous replacement of the RV free wall myocardium 
in ≥1 sample, with or without fatty replacement of tissue on 
endomyocardial biopsy 
 
Residual myocytes 60% to 75% by morphometric analysis (or 50% to 
65% if estimated), with fibrous replacement of the RV free wall 
myocardium in ≥1 sample, with or without fatty replacement of tissue 
on endomyocardial biopsy 
III. Repolarisation abnormalities 
 
Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in 
individuals >14 years of age (in the absence of complete right bundle-
branch block QRS ≥120 ms) 
 
Inverted T waves in leads V1 and V2 in individuals >14 years of age (in 
the absence of complete right bundle-branch block) or in V4, V5, or V6 
Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of 
age in the presence of complete right bundle-branch block 
IV. Depolarisation/conduction abnormalities 
 
Epsilon wave (reproducible low-amplitude signals between end of QRS 
complex to onset of the T wave) in the right precordial leads (V1 to V3) 
 
Late potentials by SAECG in ≥1 of 3 parameters in the absence of a QRS 
duration of ≥110 ms on the standard ECG 
Filtered QRS duration (fQRS) ≥114 ms 
Duration of terminal QRS <40 mV (low-amplitude signal duration) ≥38 
ms 
Root-mean-square voltage of terminal 40 ms ≤20 mV 
Terminal activation duration of QRS ≥55 ms measured from the nadir 
of the S wave to the end of the QRS, including R0, in V1, V2, or V3, in 
the absence of complete right bundle-branch block 
V. Arrhythmias 
 
Nonsustained or sustained ventricular tachycardia of left bundle-
branch morphology with superior axis (negative or indeterminate QRS 
in leads II, III, and aVF and positive in lead aVL) 
 
Nonsustained or sustained ventricular tachycardia of RV outflow 
configuration, left bundle-branch block morphology with inferior axis 
(positive QRS in leads II, III, and aVF and negative in lead aVL) or of 
unknown axis 
 >500 ventricular extrasystoles per 24 hours (Holter) 
VI. Family history 
 
ARVC/D confirmed in a first-degree relative who meets current Task 
Force criteria 
ARVC/D confirmed pathologically at autopsy or surgery in a first-degree 
relative 
Identification of a pathogenic genetic variant categorised as associated 
or probably associated with ARVC/D in the patient under evaluation 
 
History of ARVC/D in a first-degree relative in whom it is not possible or 
practical to determine whether the family member meets current Task 
Force criteria 
Premature sudden death (<35 years of age) due to suspected ARVC/D 
in a first-degree relative 
ARVC/D confirmed pathologically or by current Task Force Criteria in 
second-degree relative 
 RV – Right Ventricle; PLAX – Parasternal Long Axis; RVOT – Right Ventricular Outflow Tract; PSAX – Parasternal Short Axis; BSA – 
body surface area;  MRI – Magnetic Resonance Imaging; SAECG – Signal-averaged electrocardiogram; ECG – Electrocardiogram; 




1.1.1.1. Molecular genetics of ARVC 
A familial background of ARVC has been demonstrated in at least 50% of cases, with the 
disease typically having an autosomal dominant pattern of inheritance.16,17 The penetrance 
of ARVC is reduced and frequently age-dependent, while affected relatives often have 
variable and incomplete disease expression.7,18 A number of genetic loci have been linked to 
ARVC to date, and disease-associated genetic variants have been identified at the majority 
of these loci (Table 1.2). 
Among the genes reported to cause ARVC, the main genetic causes reported to date are 
variants in the plakophilin 2 (PKP2), desmoplakin (DSP), desmocollin 2 (DSC2), desmoglein 2 
(DSG2) and junction plakoglobin (JUP) genes which encode proteins forming part of the 
desmosome. Desmosomes are cell adhesion junctions particularly abundant in tissues 
subjected to a high amount of mechanical stress, such as the heart and the skin (Figure 
1.2).19 Disease-associated variants in these genes have been reported in up to 50% of ARVC 
cases in various patient cohorts worldwide.20 The main contributor to ARVC is the PKP2 
gene, accounting for 11-51% of disease-associated variants to date.21 Studies conducted in 
our laboratory have screened patients with ARVC for variants in the desmosomal genes and 
have detected a disease-associated variant prevalence of 21.5%.22 However, variants in 
desmosomal genes demonstrate incomplete penetrance and variable expressivity, 
suggesting that genetic modifiers and environmental factors may play a role in the etiology 
of these disorders.8 There have also been reports of patients harbouring more than one 
desmosomal gene variant, either in the same gene or in two different genes (compound 
heterozygosity), with the presence of multiple variants causing a more severe ARVC 
phenotype.23 
In addition to desmosomal genes, other genetic causes of ARVC include TMEM43,24,25 
RyR2,26 TGFβ3,27 PLN,28 CTNNA3,29 DES,30 TTN31 and LMNA.32 A number of these genes have 
also been implicated in DCM (PLN, DES, TTN and LMNA) as well as HCM (DES, TTN, RyR2).10 
6 
Figure 1.2: Structure of the desmosome. DSP – desmoplakin; JUP – Junction plakoglobin; 
PKP2 – Plakophilin-2; DSC2 – Desmocollin-2; DSG2 – Desmoglein-2 
1.1.1.2. Mechanism of disease 
Several mechanisms have been proposed to explain the link between desmosomal gene 
variants and ARVC, one such mechanism being the degeneration-inflammation model of 
desmosomal dysfunction. In this model, desmosomal variants resulting in desmosomal 
dysfunction could impair cell-cell adhesion or intermediate filament function or both, 
dependent on the effect of the variant on protein structure and function.7 This would cause 
a reduction in the ability of the tissue to withstand mechanical stress, causing cellular 
detachment and necrosis, which may be accompanied by inflammation. When the 
regenerative capacity of the myocardium is exceeded, the myocytes are instead replaced 
with fibrous and/or fatty tissue.7,8 
Another proposed disease model is the transdifferentiation model, involving the Wnt/β-





proliferation and apoptosis.7,8 The Wnt/β-catenin signalling pathway usually promotes gene 
expression which causes cell differentiation to a cardiomyocyte state and suppression of the 
expression of genes that promote adipogenesis and fibrogenesis.7,8 Plakoglobin (JUP – one 
of the desmosomal genes), also known as γ-catenin, is structurally and functionally similar 
to β-catenin and can shuttle between the cell periphery and the nucleus. In the event of a 
genetic variant that affects the localisation of plakoglobin (e.g. a variant that suppresses the 
expression of desmoplakin), plakoglobin translocates to the nucleus where it can take the 
place of β-catenin and cause upregulation of adipogenic and fibrogenic genes.7,8 
A recent study has implicated the Hippo/Yes-associated protein (YAP) pathway in the 
pathogenesis of ARVC.33 This pathway plays a role in the regulation of cell proliferation and 
organ growth and has recently been linked to control of cardiomyocyte proliferation and 
heart size.34-37 In the event of a desmosomal gene variant causing desmosomal instability, 
neurofibromin 2 (NF2) (upstream of the Hippo pathway) is activated, resulting in cascade 
phosphorylation of the Hippo kinases, inactivation of YAP (downstream of the Hippo 
pathway) and enhanced adipogenesis, one of the hallmarks of ARVC.33,37 
Other studies have shown evidence of gap junction remodelling and aberrant calcium 
homeostasis in the presence of desmosomal gene variants.8 It is not known which of these 
mechanisms are responsible for the phenotype of ARVC, or whether there is interplay 




Table 1.2: Genetic loci associated with ARVC to date 






ARVD1 14q23-q24 TGFβ3 Transforming Growth Factor-β3 AD 38 27 
ARVD2 1q42-q43 RyR2 Ryanodine Receptor 2 AD 39 26 
ARVD3 14q12-q22 - Unknown AD 40 - 
ARVD4 2q32.1-q32.3 - Unknown AD 41 - 
ARVD5 3p23 TMEM43 Transmembrane protein 43 AD 42 24 
ARVD6 10p12-p14 - Unknown AD 43,44 - 
ARVD7 10q22 - Unknown AD 45 - 
ARVD8 6p24 DSP Desmoplakin AD/AR 46 46 
ARVD9 12p11 PKP2 Plakophilin 2 AD 47 47 
ARVD10 18q12.1- q12.2 DSG2 Desmoglein 2 AD 48 48 
ARVD11 18q12.1 DSC2 Desmocollin 2 AD 49 49 
ARVD12 / Naxos 17q21 JUP Junction Plakoglobin AD 50 51 
 
ARVD – Arrhythmogenic Right Ventricular Dysplasia; AD – autosomal dominant; AR – autosomal recessive 
9 
 
1.1.2. Cardiomyopathy Research in South Africa 
To the best of my knowledge, there are only three original scientific studies of ARVC in 
South Africa that have been reported to date.12,13 The initial report of ARVC in Africa was 
published by Munclinger and colleagues in 2000.12 Mokhobo and Mntla had reported cases 
of right ventricular cardiomyopathy a few years ahead of this report but it is not known 
whether these cases met the diagnostic criteria of ARVC or not.52 The ARVC Registry of 
South Africa was established in 2004 by CASSA, and the preliminary reports from this 
registry suggest that ARVC occurs in all population groups and that the frequency of familial 
disease, clinical features and outcome are similar to observations from other parts of the 
world.13 
Molecular genetic studies on ARVC in Africa have largely focused on variants in the 
desmosomal genes. A study by Mbele and colleagues (available in PhD thesis form only) 
reported disease-associated variants in desmosomal genes in patients with ARVC.22 In 
particular, this study reported the PKP2 c.1162C>T founder variant in multiple South African 
ARVC families of European descent.22 Another unpublished study was from my MSc thesis, 
which reported variants in the DSP desmosomal gene in patients with ARVC.53 However, the 
genetic factors responsible for the majority of ARVC cases in South Africa remain unknown; 
the need to define the genetic factors in South Africans with ARVC serves as the basis for 
this thesis. 
A relatively new candidate gene for ARVC is the phospholamban (PLN) gene. Recent reports 
by van der Zwaag and colleagues have reported disease-associated variants in the PLN gene 
that encode the phospholamban protein in patients with ARVC.28,54 They detected a founder 
variant in PLN that was common among individuals from the Dutch population as well as 
populations known to share common ancestry with this population.28,54 As many South 
African Caucasian individuals also share common ancestry with this population, there was 
the possibility that the PLN founder variants may have been associated with ARVC in this 





1.2. The ACM2 family 
We previously reported a four-generation South African family of northern European 
descent with a dominant form of ARVC (family ACM2).44 Extensive genetic analysis was 
previously performed and involved techniques such as exclusion mapping and whole 
genome single nucleotide polymorphism (SNP) linkage analysis.44,55  Exclusion mapping 
resulted in the exclusion of all known ARVC loci with the exception of the ARVC6 locus on 
chromosome 10p12-p14 (Table 1.2) which showed borderline evidence of linkage (highest 
LOD score of 2.93).44 Screening of the coding regions of the 15 genes that occur at this locus 
revealed no disease-associated variants.55 Genome-wide linkage studies using SNP arrays 
revealed suggestive evidence of linkage at chromosomes 1, 4, 10, and 12 (Two-point LOD 
scores: 2.73, 2.78, 2.72 and 2.56 respectively), with the highest multipoint LOD score being 
2.79 for chromosomes 4 and 10.55  However, no disease-associated variants were identified 
at these loci. 
The design of this current study focused on finding the disease-associated variant/s in the 
ACM2 family using three different approaches. First, we used candidate gene screening of 
the phospholamban gene (PLN) (chapter 2) then genome-wide copy number variant (CNV) 
analysis (chapter 3), and finally, whole exome sequencing (chapter  4) to identify the 




We propose that the disease-causing genetic variant in the ACM2 family is likely to lie within 
the exome, as more than 85% of disease-associated genetic variants lie within this region, 
and there is a strong possibility that this is the case in this family, particularly due to the 
dominant pattern of inheritance of the disease. 
Although many genes have been associated with ARVC to date, disease-associated genetic 
variants remain to be identified in a large proportion of individuals with this disease. In the 
ACM2 family with autosomal dominant ARVC, no genetic cause has been identified since the 
family was first identified in 1996. We hypothesise that the genetic cause of disease in this 
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family may lie in either PLN or a novel ARVC genetic locus and may involve a gene that has 
not been previously associated with this disease.  
 
1.4. Objective of the project 
To identify the genetic cause of disease in the ACM2 family with autosomal dominant ARVC 
 
1.5. Specific aims 
The specific aims of this project were:  
(1) To screen the ACM2 family for disease-causing variants in PLN and determine the 
prevalence of variants in this gene in other cases of cardiomyopathy (ARVC, DCM, PCM and 
HCM). If no disease-causing variant in PLN is found in the ACM2 family, then – 
(2) To screen the ACM2 family for the presence of disease-causing copy number variations 
(CNVs). If no pathogenic CNV is found in the ACM2 family, then – 





SCREENING OF THE PHOSPHOLAMBAN (PLN) GENE IN THE ACM2 
FAMILY AND OTHER CASES OF CARDIOMYOPATHY 
 
2.1. Introduction 
Cardiomyopathy is caused by genetic factors in a large proportion of cases, and our 
knowledge of these factors has increased monumentally in recent years.56 Arrhythmogenic 
right ventricular cardiomyopathy (ARVC) has been associated with genes involved in cell-to-
cell adhesion. Dilated cardiomyopathy (DCM) has been associated with genes involved in 
maintaining the structural integrity of the heart, muscle contraction and mitochondrial 
function while hypertrophic cardiomyopathy (HCM) is associated mainly with genes coding 
for proteins of the sarcomere.57 
The ARVC Registry of South Africa was established in 2004 by the Cardiac Arrhythmia 
Society of Southern Africa (CASSA).58 Suspected cases of ARVC are referred to the co-
ordinating centre in the Cardiac Clinic at Groote Schuur Hospital, Cape Town. As of 
September 2015, 85 unrelated ARVC patients have been enrolled in the registry.13 This 
registry houses one of our largest ARVC families (ACM2) and includes 20 members – six of 
whom are affected (Figure 2.1).44,55 
The design of this study focused on finding the disease-causing variant/s in this family. Their 
ancestry traces back to that of northern European descent and an autosomal dominant 
inheritance pattern was noted. Extensive genetic analysis was previously performed and 
involved techniques such as whole genome SNP linkage analysis; unfortunately, the data 
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2.2. The phospholamban (PLN) gene 
Recently, variants in the phospholamban (PLN) gene have been associated with ARVC.28 
Variants in this gene had previously been reported in cases of DCM28,59-62 or HCM.63,64 PLN is 
located on the long arm of chromosome 6 (6q22.1) and encodes phospholamban (PLN), a 52 
amino acid protein with four domains: domains Ia, Ib and the loop domain located in the 
cytoplasm region and domain II located in the transmembrane region (Figure 2.2).65 PLN 
exists as a monomer or forms a homopentamer in a pinwheel topology.65 These two forms 
of PLN exist in equilibrium, a fact that is known to be important for PLN activity.65 PLN plays 
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Figure 2.2: Domains of the PLN protein (adapted from Ha et al. 201165) 
 
 
2.2.1. The Role of PLN in Cardiac Contractility 
Adrenaline and other β-agonists bind to and activate β-adrenergic receptors on the cell 
membrane (Figure 2.3).66 Gs proteins then stimulate adenylate cyclase, which leads to the 
formation of cyclic adenosine monophosphate (cAMP).66 The rise in cAMP concentration 
activates cAMP-dependent protein kinase A (PKA)66. PKA then phosphorylates proteins such 
as PLN that play vital roles in cardiac function.66 
 
PLN is involved in regulation of the sarcoplasmic reticulum (SR) Ca2+ ATPase pump  
(SERCA2a) that regulates Ca2+ reuptake into the sarcoplasmic reticulum and thereby allows 
muscle relaxation (Figure 2.3).66 In its unphosphorylated state, PLN inhibits the activity of 
the SERCA2a pump, causing muscle contraction.66 Phosphorylation by PKA allows PLN to be 


























regulation include the cardiac ryanodine receptor (RyR), sodium calcium exchangers (NCX), 




Figure 2.3: The role of PLN in cardiac contractility (from MacLennan and Kranias66) 
Gsα – G-protein subunit alpha; NCX – Sodium calcium exchanger; DHPR – Dihydropyridine receptor; ATP – 
Adenosine triphosphate; PMCA – Plasma membrane Ca
2+
 ATPase; cAMP – Cyclic adenosine monophosphate; 
RyR – Ryanodine receptor; PKA – Protein kinase A; PLN – Phospholamban; AKAP – A-kinase anchoring protein; 
PP1 – Protein phosphatase 1; RgI – Regulatory binding subunit A; SR – Sarcoplasmic reticulum; Na
+
 – Sodium 
ion; Ca
2+
 – Calcium ion 
 
2.2.2. Variants in PLN associated with Disease 
As mentioned above, variants in PLN have previously been associated with various types of 
cardiomyopathy including DCM, HCM and more recently ARVC. Van der Zwaag and 
colleagues recently identified the p.R14del variant in the PLN gene in patients with ARVC as 
well as patients with DCM.28 This variant was determined to be a founder variant in the 
genetically isolated Newfoundland population, and associated with autosomal dominant 
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ARVC as well as with DCM.28 The current Newfoundland population is known to share 
ancestors with populations from New Zealand, Australia and South Africa, with the founder 
population having originated in Europe.54 As variants in PLN have been associated with 
ARVC, DCM and HCM in populations who share common ancestors with the South African 
Caucasian population, we hypothesise that PLN may account for some of the genetic causes 




The objective of this study was to determine whether PLN variants cause cardiomyopathy in 
the South African population with ARVC, DCM, HCM and peripartum cardiomyopathy 
(PPCM). By screening large numbers of affected individuals, we aimed to provide a definitive 
perspective on the contribution of PLN variants to the etiology of cardiomyopathy in South 
Africa. 
 
2.4. Specific aims 
(1) To screen for DNA variants in PLN in probands with ARVC, DCM, HCM and PPCM, and (2) 




This study involved screening patients with cardiomyopathy for variants in PLN by high 
resolution melt (HRM) analysis and Sanger DNA sequencing, as well as performing 
haplotype analysis to determine the presence of possible founder genetic variants. 
 
2.5.1. Cohorts 
The patient cohort consisted of ARVC, DCM, PPCM and HCM patients and ethnically 
matched controls. Informed consent was obtained from all participants (Appendix 1). These 
patients had been previously screened for variants in the desmosomal genes known to 
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cause ARVC (DSP, PKP2, DSC2, DSG2 and JUP) and were found not to harbour any disease-
causing variants in these genes.13,22,53 
 
2.5.1.1.  ARVC Cases 
ARVC cases were investigated at the Cardiac Clinic, Groote Schuur Hospital, Cape Town, 
South Africa, and enrolled in the ARVC registry of South Africa.67 A standardised case report 
form is completed for all participants and available family members with ARVC, DCM and 
other cardiomyopathies.  Information on presenting symptoms, family history, 
electrocardiographic findings, cardiac imaging studies, histology, and outcome was 
collected. Informed consent was obtained from all participants (Appendix 1). 
A diagnostic panel consisting of a group of cardiologists determined, by consensus, whether 
or not patients met the 2010 diagnostic criteria of ARVC.15 The participants were classified 
as having definite ARVC (if Task Force criteria were met), probable or possible ARVC (if some 
criteria were met and no alternative diagnosis was found), or not having ARVC (if there was 
no evidence of ARVC and/or an alternative diagnosis was present). The diagnosis of ARVC in 
first-degree relatives of affected individuals was made based on the modified criteria of 
Hamid and colleagues.68 
 
2.5.1.2.  DCM, PPCM and HCM Cases 
Index cases were recruited from the Cardiac Clinic, Groote Schuur Hospital in Cape Town; 
the University of Cape Town Private Academic Hospital in Cape Town; Inkosi Albert Luthuli 
Hospital in Durban; as well as Milpark Hospital, Chris Hani Baragwanath Hospital and 
Sunninghill Hospital in Johannesburg. 
A standardised case report form was completed for all study participants, which included 
information regarding presenting symptoms, electrocardiographic findings, cardiac imaging 
studies, family history and outcome. Blood samples were collected for molecular genetic 
testing. Subjects were reviewed by a panel of cardiologists to determine if the index cases 
fulfilled the diagnostic criteria for DCM, PPCM or HCM established by the European Society 
18 
 
of Cardiology Working Group on Myocardial and Pericardial Diseases.5 Patients determined 
to have secondary causes of cardiomyopathy or left ventricular dysfunction (including 
hypertension, valvular heart disease, diabetes, coronary artery disease or sepsis) were 
excluded from the study. 
 
2.5.1.3. Controls 
Healthy, anonymous blood donors with no history of heart disease from the Western 
Province Blood Transfusion Service provided blood samples for DNA isolation. Self-reported 
ethnicity of these individuals was Black African, Caucasian, Mixed ancestry and Indian. 
Controls were matched with cardiomyopathy cases according to ethnic origin. 
 
2.5.2. DNA Isolation and Storage 
Sample DNA was extracted from 5-10ml blood using the PureGeneTM DNA Purification 
System (Gentra systems) according to the manufacturer’s instructions.  Written informed 
consent was obtained from all individuals enrolled in the study (Appendix 1).  Extracted DNA 
samples were stored in 1.5ml Eppendorf tubes at -80°C for long term storage.  All individuals 
were given codes to anonymise the samples and ensure patient confidentiality. 
 
2.5.3. DNA Quality Control 
All DNA samples were run on a 1% agarose gel (Appendix 2.2) to verify integrity. Sample 
concentration was determined with the Qubit® Fluorometer (Life technologies) using the 
Qubit® dsDNA BR Assay Kit and also with the NanoDrop™ 2000 Spectrophotometer. The 
NanoDrop™ 2000 Spectrophotometer was also used to verify that samples were free of 
contaminants. 
 
2.5.4. High Resolution Melt Analysis 
HRM analysis with the RotorGene 6000 (Corbett Life Sciences) was used for the screening of 
PLN. Genetic variant detection by HRM analysis involves two steps: amplification of the DNA 
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sequence of interest using PCR and analysis of the produced amplicon by HRM.  With the 
RotorGene 6000 (Corbett Life Sciences), these two steps can be combined into a single 
procedure where DNA samples are amplified and then immediately subjected to HRM 
without the need for human intervention. 
 
2.5.4.1. Primer design 
Primer sequences were selected manually by (1) referring to the annotated gene sequences, 
and (2) analysing the selected sequences using the IDT OligoAnalyzer 
(https://eu.idtdna.com/calc/analyzer) and NCBI BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) web-based tools in order to determine the optimal 
primer sequences for the amplification of the gene.     
The primers were required to have: (1) good sequence diversity with minimal sequence 
repeats and secondary structure, (2) a length of between 18 and 25 base pairs (bp), (3) a 
melting temperature (Tm) of between 45°C and 65°C, (4) a GC content of between 45% and 
65%, and (5) a G or C clamp at the 3’ end. If all criteria could not be met, the best primer 
option was chosen. The amplicon sequences were also restricted to a 250-350bp length, as 
increased amplicon size is known to lead to decreased resolution in amplicon screening and 
genetic variant detection with HRM. Primers were designed to span the exonic regions of 
the PLN gene (Table 2.1). These primers were used for combined real-time PCR and HRM 
analysis as well as for DNA sequencing. 
 









F CCA GGC TAC CTA AAA GAA GAC 21 52.6 47.6 
332 





2.5.4.2. HRM Protocol 
Probands with ARVC, DCM, PPCM and HCM were screened for disease-associated genetic 
variants by comparing sample HRM profiles to those of control samples known to be 
negative for these diseases. The reagents used for the combined real-time PCR and HRM of 
the PLN gene are shown in Table 2.2 and the reaction conditions are shown in Table 2.3. 
Table 2.2: Reagents for the PCR and HRM of the PLN gene 
REAGENT (STOCK CONCENTRATION) 
FINAL CONCENTRATION / VOLUME PER 
REACTION 
Forward Primer (20 µM) 0.8 µM / 0.5 µl 
Reverse Primer (20 µM) 0.8 µM / 0.5 µl 
dNTPs (20 µM) (Bioline ) 0.8 µM / 1 µl 
GoTaq Polymerase (5 U/ ul ) (Promega) 0.5 U / 0.1 µl 
GoTaq FlexiBuffer (5X) (Promega) 1 X / 5 µl 
MgCl2 (25 mM) (Promega) 1.5 mM / 3 µl 
EvaGreen dye (Anatech) 1X / 1 µl 
DNA 200 ng 
FINAL REACTION VOLUME 25 µl 
 










CONDITION TEMPERATURE (TIME) 




           95°C – 5 seconds 
           55°C – 10 seconds          50 cycles 
           72°C – 10 seconds 
High Resolution Melt 




2.5.5. Sequence Analysis 
DNA sequencing was performed on all samples that showed a change relative to the 
controls with HRM analysis. 
 
2.5.5.1. HRM product purification 
After analysis by HRM, the samples marked for sequencing were purified using the Shrimp 
Alkaline Phosphatase and Exonuclease I enzymes. The reagents used are shown in Table 2.4 
and the reaction conditions are shown in Table 2.5. 
 




Exonuclease I (New England Biolabs) 1 U / 0.1 µl 
Shrimp Alkaline Phosphatase (Promega) 2 U  / 1 µl 
HRM Product 5 µl 
FINAL REACTION VOLUME 20 µl 
 
 
Table 2.5: Optimised temperature cycling conditions for the purification of the PLN HRM 
Products 
CONDITION TEMPERATURE (TIME) 
Incubation 37°C – 1 hour 
Deactivation 75°C – 15 min 
 
Sequencing was performed with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, Foster City, CA, USA). The reagents used for the sequencing reactions are 




Table 2.6: Reagents for the sequencing of the PLN HRM Products 
REAGENT 
FINAL CONCENTRATION / VOLUME  PER 
REACTION 
Forward Primer (20 µM) 2 mM / 2 µl 
HRM product 3 μl 
BigDye ® Terminator v3.1. Ready Reaction 
Mix (Applied Biosystems) 
2 μl 
5 X Sequencing Buffer (Applied 
Biosystems) 
1 X 
FINAL REACTION VOLUME 20 µl 
 
 
Table 2.7: Optimised temperature cycling conditions for the sequencing of the PLN HRM 
Products 
CONDITION TEMPERATURE (TIME) 




 96°C – 30 seconds 
                     50°C – 15 seconds    25 cycles 
60°C – 4 minutes 
 
2.5.5.2.  Capillary Electrophoresis 
The sequencing products were analysed using capillary electrophoresis with the ABI PRISM® 
3130xl Genetic Analyser (Applied Biosystems, Foster City, CA, USA) at the Stellenbosch DNA 
Sequencing Unit (Department of Genetics, Stellenbosch University, Cape Town). 
 
2.5.5.3.  Sequencing Alignment and Analysis 
The DNA sequences generated in these experiments were aligned with the wild type 
sequence obtained from the Ensembl database (http://www.ensembl.org/) and analysed 
using the BioEdit Sequence Alignment Editor (Ibis Biosciences, Carlsbad, CA, USA). 
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2.5.6. Population Screening 
For variants of interest, 200 ethnically matched control chromosomes were screened by 
HRM analysis and Sanger sequencing to determine the prevalence of these variants in the 
general population. 
2.5.7. Bioinformatic Analysis 
The novelty of detected variants was determined by searching the 1000 Genomes 
(http://browser.1000genomes.org/index.html), National Heart, Lung and Blood Institute 
Exome Variant Server Exome Sequencing Project (NHLBI-EVS ESP) 
(http://evs.gs.washington.edu/EVS/), NCBI dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and 
Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org/) databases, as well 
as literature review. Bioinformatic analysis of the PLN variants of interest was conducted 
using various bioinformatic tools to assess the impact of the variants on PLN structure and 
function at the messenger ribonucleic acid (mRNA) and protein levels. 
2.5.7.1. Bioinformatic Analysis of the Effect of Nucleic Acid Substitutions on Exon/Intron 
Splice Sites 
In order to determine whether novel sequence variants in PLN caused a change in mRNA 
splicing, the sequences were analysed using the Berkeley Drosophila Genome Project 
NNSPLICE 0.9 (http://www.fruitfly.org/seq_tools/splice.html)69, SplicePort 
(http://spliceport.cbcb.umd.edu/)70, Human Splicing Finder (http://www.umd.be/HSF/)71 
and NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/)72 web-based analysis tools. 
2.5.7.2. Bioinformatic Analysis of the Effect of Nucleic Acid Substitutions on Exonic Splice 
Enhancer (ESE) Sites 
In order to determine whether novel sequence changes could disrupt existing ESEs, 
sequences were analysed using the ESEFinder web-based tool (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home).73 
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2.5.7.3. Bioinformatic Analysis of the Effect of Nucleic Acid Substitutions on the Secondary 
Structure of RNA 
Control and mutant sequences were analysed using the Mfold 
(http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form)74 and RNAfold 
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi)75 web-based tools to predict RNA folding. 
2.5.7.4. Bioinformatic Analysis of the Effect of Amino Acid Substitutions on Protein Structure 
and Function 
The Align-GVGD (http://agvgd.iarc.fr/agvgd_input.php)76, PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/)77 and SIFT (Sorting Intolerant From Tolerant) 
(http://sift.jcvi.org/www/SIFT_enst_submit.html )78 bioinformatic tools were used to predict 
whether non-synonymous variants had deleterious effects on the PLN protein. The 
MutationTaster tool (http://www.mutationtaster.org/)79 was used to predict whether 
variants would have an overall effect on protein function. 
2.5.8. Haplotype analysis 
DNA samples for microsatellite analysis of the family described by Schmitt et al.61 were 
obtained from Professor Christine Seidman (Department of Genetics, Harvard Medical 
School, Boston, MA 02115, USA). Microsatellite markers were used to construct haplotypes 
of the PLN gene. The markers included were D6S45454, PLN-200K54, PLN+200K54 and 
D6S412.54 The primers for the PCR amplification of these markers are listed in Table 2.8, the 
reagents are listed in Tables 2.9 (D6S454, PLN+200K and D6S412) and 2.10 (PLN-200K) and 
the reaction conditions in Table 2.11.  
PCR products were run on a 2% agarose gel (Appendix 2.3) for verification of reaction 
success and product size and specificity. These products were then analysed using capillary 
electrophoresis with the ABI PRISM® 3130xl Genetic Analyser (Applied Biosystems, Foster 
City, CA, USA) at the Division of Human Genetics, University of Cape Town. Haplotypes were 
constructed using Cyrillic v2.0 (Cyrillic Software, United Kingdom). 
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Table 2.8: Details for PLN microsatellite marker primers 
PRIMER SEQUENCE TAG 
POSITION RELATIVE 








D6S454_F CAATGCTGCCCTGAGATTG 5’ HEX 
-3 500 000 
19 54.1 52.6 
136 
D6S454_R TTATTCAGAATTTCTTGCCTATAG - 24 48.7 29.2 
PLN-200K_F ACTCCAGCCTGGGTGACAAATCAAG 5’ HEX 
-200 000 
25 61.1 52.0 
451 
PLN-200K_R AGTCTCAGCTCCACCATTTG - 20 54.8 50.0 
PLN+200K_F TTGTCAGAGGGCTGTGCTTC 5’ HEX 
+200 000 
20 57.5 50.0 
332 
PLN+200K_R GTCAGTCAGGAGGATAGTTC - 20 51.6 50.0 
D6S412_F GCACAATTTTAGAAGGTTCACAAAG 5’ HEX 
+1 650 000 
25 53.3 36.0 
208 




Table 2.9: Reagents for the PCR of the D6S454, PLN+200K and D6S412 PLN microsatellite 
markers 
 
REAGENT (STOCK CONCENTRATION) 
FINAL CONCENTRATION / VOLUME PER 
REACTION 
Forward Primer (20 µM) 0.8 µM 
Reverse Primer (20 µM) 0.8 µM 
dNTPs (20 µM) (Bioline ) 0.8 µM 
GoTaq Polymerase (5U/ ul ) (Promega) 0.5 U 
GoTaq FlexiBuffer (5X) (Promega) 1 X 
MgCl2 (25 mM) (Promega) 1.5 mM 
DNA 200 ng 
FINAL REACTION VOLUME 25 µl 
 
Table 2.10: Reagents for the PCR of the PLN-200K PLN microsatellite marker 
 
REAGENT (STOCK CONCENTRATION) 
FINAL CONCENTRATION / VOLUME PER 
REACTION 
Forward Primer (20 µM) 0.8 µM 
Reverse Primer (20 µM) 0.8 µM 
dNTPs (20 µM) (Bioline ) 0.8 µM 
GoTaq Polymerase (5U/ ul ) (Promega) 0.5 U 
GoTaq FlexiBuffer (5X) (Promega) 1 X 
MgCl2 (25 mM) (Promega) 0.75 mM 
DNA 200 ng 


















*- D6S454 – 56°C, PLN-200K – 63°C, PLN+200K and D6S412 – 59°C 
 
2.6. Results 
The cohorts screened for variants in PLN included 85 ARVC cases, 95 DCM cases, 69 PPCM 
cases and 40 HCM cases. The characteristics of the ARVC, DCM, PPCM and HCM cohorts are 















CONDITION TEMPERATURE (TIME) 




94°C - 30 seconds 
                         * - 45 seconds   33 cycles 
72°C - 50 seconds 
Final Elongation 72°C - 7 minutes 
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Table 2.12: Characteristics of cardiomyopathy cohorts screened for variants in PLN 
CHARACTERISTIC ARVC PATIENTS DCM PATIENTS PPCM PATIENTS HCM PATIENTS 
No. of Patients 85 95 69 40 




















Average age in 
years (±SD) 
46±16 54±15 52±15 43±14 































Screening of PLN identified the previously reported c.25C>T (p.R9C)61,62 variant in individual 
DCM320.1. This variant changed an amino acid that was highly conserved among Pan 
troglodytes, Macaca mulatta, Felis catus, Mus musculus and Gallus gallus (Figure 2.4). 
Population screens revealed this variant to be absent in 200 ethnically matched control 
chromosomes, which is in agreement with what was shown by Schmitt and colleagues, who 
found this variant to be absent in more than 200 control chromosomes.61 It was not 
reported in the Exome Variant Server or ExAC databases, but was reported as rs111033559 
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Figure 2.4: Identification of the c.25C>T (p.R9C) variant. (a) HRM and derivative graphs 
showing control samples (red) and variant sample (blue) amplicon melting (Y-axis for top 
graph – Normalised fluorescence; Y-axis for bottom graph – dF/dT); (b) Electropherogram 




Detailed investigation into the family history of this proband pointed to an autosomal 
dominant inheritance pattern of severe DCM in this family (Figure 2.5). The proband 
(DCM320.1; II:2) presented with DCM after pregnancy and had a heart transplant at the age 
of 35 years while the proband’s son (DCM320.3; III:1) was similarly affected with DCM and 
had also undergone a heart transplant at the age of 25 years. The proband’s younger sister 






H. sapiens    1 MEKVCYLTRSAIRRAST 17 
P. troglodytes    1 MEKVCYLTRSAIRRAST 17 
M. mulatta    1 MEKVCYLTRSAIRRAST 17 
F. catus     1 MEKVCYLTRSAIRRAST 17 
M. musculus    1 MEKVCYLTRSAIRRAST 17 




age of 39 years. Although the proband’s daughter (DCM320.4; III:3) showed early signs of 
DCM on echocardiography, the diagnosis was not confirmed.  Further enquiry also revealed 
that the proband’s mother had died of a heart condition at the age of 36 years. However, 
we were not able to confirm whether this individual was affected with DCM. 
Subsequent variant screening of PLN for the available members of this family found the 
c.25C>T (p.R9C) variant in the proband’s affected son (DCM320.3; Individual III:1) and 
daughter (DCM320.4; Individual III:3) as well as the proband’s affected sister (Individual 
II:3), reflecting segregation of the c.25C>T variant with DCM in this family (Figure 2.5). No 



















Figure 2.5: Pedigree of family DCM320 showing the c.25C>T variant and individuals with 
DCM.  SB: Stillbirth;     + : c.25C>T positive;     – : c.25C>T negative. 
 
Bioinformatic analysis revealed that this variant was predicted to be disease-causing by the 
MutationTaster, PolyPhen-2 and Align GVGD bioinformatic tools. This variant was also 









bioinformatic tools (Figure 2.6). The ESEfinder tool predicted that this variant would alter 
SRSF1 and SRSF5 exonic splice enhancer recognition sites (Figure 2.7). 
 
 




Figure 2.6: MFold and RNAfold predictions for wild type and c.25C>T PLN. (a) MFold wild 
type PLN predicted structure; (b) MFold c.25C>T PLN predicted structure; (c) RNAfold wild 



















Figure 2.7: ESEfinder results for wild type and c.25C>T PLN. (a) 
ESEfinder predictions for wild type PLN. (b) ESEfinder predictions for 
c.25C>T PLN (SRSF – Serine/arginine-rich splicing factors; IgM – 
Immunoglobulin M; BRCA1 – Breast Cancer 1, Early Onset). 
 
 
As the PLN c.25C>T variant was initially reported in a single family of European descent61, it 
was important to determine if these variants arose independently or if they were inherited 
from a common ancestor, possibly as early as the 17th century when the European 
colonisation of South Africa began. Haplotypes were constructed using the microsatellite 
markers mentioned above (D6S454, PLN-200K, PLN+200K and D6S412)54 spanning 5.15Mb 
across the PLN gene. In the DCM320 family, the PLN c.25C>T variant was found to be part of 
a disease-specific haplotype spanning this 5.15Mb region (Figure 2.8). The PLN c.25C>T 
variant was found to be part of a different haplotype in the family described by Schmitt et 
al. (Figure 2.8).61 We were unable to determine the possibility of common ancestry between 
the South African family and the Polish variant carrier, as this individual was only reported 
recently.62 
  SRSF1  
  SRSF1 (IgM-BRCA1)  
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Figure 2.8: Haplotype analysis. (A). Pedigree of the DCM320 family. (B). Pedigree of the 
MDO DCM family. 
 
In the original report of this PLN c.25C>T (p.R9C) variant by Schmitt and colleagues61, it was 
reported that this variant was associated with an autosomal dominant inheritance pattern 
of DCM which was characterised by increased cardiac chamber dimensions, decreased 
contractile function at 20-30 years of age and progression to heart failure within 5-10 years 

















individual harbouring this variant who was reported by Truszkowska and colleagues 
exhibited onset of severe DCM at the age of 21 and required a heart transplant at the age of 
22.62 There is consequently strong evidence that the PLN c.25C>T (p.R9C) variant is disease-
causing in the DCM320 family, based on segregation with disease in this family and previous 
reports of segregation with DCM by Schmitt61 and Truszkowska.62 We did not detect any 
other variants in PLN. 
 
2.7. Discussion 
We screened patients with ARVC, DCM, HCM or PPCM for variants in PLN and detected the 
previously reported c.25C>T variant in individual DCM320.1. We also detected this variant in 
three of this individual’s family members, two of whom were severely affected with DCM 
and one who showed early signs of the disease, indicating segregation of this variant with 
autosomal dominant DCM in this family. This variant was previously reported as disease-
causing by Schmitt and colleagues.61 They found this variant to be associated with 
autosomal dominant DCM involving decreased contractile function at 20-30 years of age, 
increased chamber dimensions and progression to heart failure within 5-10 years following 
symptom onset, a phenotype similar to that found in the DCM320 family. It was also 
reported in an individual with severe DCM by Truszkowska and colleagues.62 
A number of PPCM cases are in reality cases of familial DCM occurring around the time of 
pregnancy. Patients with PPCM often make a full recovery after pregnancy, but others do 
not.80 Those who fail to recover after pregnancy are thought to have a genetic cause of 
disease, and that the phenotype they are displaying is DCM manifesting around the time of 
pregnancy due to the increased load placed on the heart and the rise of oxidative stress that 
occurs during this period.80 It has been shown that oxidative stress worsens the cardiotoxic 
effect of the PLN p.R9C variant,65 and the manifestation of disease after pregnancy in the 
DCM320 family appears to be a clear example of this effect. 
A transgenic mouse model harbouring the p.R9C variant is characterised by biventricular 
cardiac dilation which started at the age of 4 months, increase in heart chamber size, 
decrease in left ventricular contractility and symptoms of terminal heart failure.61 Histology 
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revealed myocyte enlargement.61 The examination of these mice showed that the p.R9C 
variant is associated with the development of DCM. 
 
An in vitro study of the mechanism of disease for this variant revealed that mutant PLN 
prevented phosphorylation of the wild type PLN by trapping protein kinase A and thus 
inhibiting phosphorylation of wild type PLN.61 Mutant cells (HEK293) displayed depressed 
calcium kinetics and delayed myocyte relaxation.61 The authors therefore concluded that 
p.R9C leads to the development of DCM by alteration of myocyte calcium kinetics and 
therefore muscle contraction and relaxation, causing the development of DCM. A study by 
Ha and colleagues showed that the p.R9C variant increases the stability of the PLN 
pentamer, preventing it from binding to Ca2+-ATPase and phosphorylation by protein kinase 
A.65 They also showed that these effects are enhanced under conditions of oxidative stress, 
suggesting that these conditions may worsen the cardiotoxic effects of the PLN p.R9C 
variant.65 A study by Yu and Lorigan demonstrated that cytoplasmic domain Ia (amino acids 
1-16) of phosphorylated PLN and p.R9C-PLN adopted a similar conformation, shifting away 
from the membrane surface, that may relate to relief of SERCA2a inhibition.81 There is 
therefore strong functional evidence that the PLN c.25C>T (p.R9C) variant causes the 
development of severe autosomal dominant DCM. 
 
Although a total of 289 South African cardiomyopathy patients (ARVC, DCM, PPCM and 
HCM) were screened in this study, only one disease-causing variant was found in PLN 
(frequency = 0.2%) illustrating that PLN is not a common cause of cardiomyopathy in South 
Africans. This is the first time that PLN has been evaluated as a potential cause of disease in 
a PPCM cohort. An earlier report by van Spaendonck-Zwarts and colleagues had examined 
PLN in a single family with PPCM but no disease-causing variants were found.82 To date, 
there are three known PLN variants (c.25C>T (p.R9C)61,62, c.40_42delAGA (p.R14del)28,60 and 
c.116T>G (p.L39X)59) associated with DCM28, one variant associated with ACM 
(c.40_42delAGA (p.R14del)28)  and two variants associated with HCM (c.1-77A>G64 and c.1-
42C>G63) (Table 2.13). The majority of these variants have been associated with severe 
cardiomyopathy. Recently, a duplication of the entire PLN gene has been reported in a 
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paediatric case of dilated cardiomyopathy.83 This is an indication of the important function 
of this gene, as variations in this gene do not appear to be well-tolerated. 
 
Table 2.13: Known PLN variants associated with cardiomyopathy 
Variant Disease 
No. of probands 
carrying variant 
Frequency in control 
chromosomes 
Reference 










c.116T>G (p.L39X) DCM 1 0/500 59 
c.1-77A>G HCM 1 0/592 64 
c.1-42C>G HCM 1 0/100 63 
 
 
We have established that the PLN c.25C>T variant forms part of a disease-specific haplotype 
spanning 5.15Mb across PLN in the DCM320 family that differed from the haplotype 
observed in the family described by Schmitt et al.61. It is therefore unlikely that this variant 
was inherited from a common ancestor. 
 
Evidence obtained from family segregation analysis (DCM320), bioinformatics and previous 
studies that have focused on the p.R9C variant allows us to conclude that this variant is 




We detected the known c.25C>T PLN variant which leads to a severe form of DCM. We have 
also shown that PLN variants are a rare cause of cardiomyopathy in South Africa. No 





COPY NUMBER VARIATION IN THE ACM2 FAMILY 
 
3.1. Introduction 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is known to be caused by various 
genetic factors, but ~50% of ARVC cases have no identified genetic cause to date.84 As 
described in chapter 2, the design of this study focused on finding the disease-causing 
variant/s in one such family (ACM2) with autosomal dominant ARVC. Extensive genetic 
analysis was previously performed using techniques such as whole genome single 
nucleotide polymorphism (SNP) linkage analysis, but no disease-causing variants were 
identified.44,55 
The ACM2 family was originally linked to the ARVC6 locus on chromosome 10 based on 
borderline statistical evidence of linkage (LOD score 2.93) (Fig. 3.1).44 However, an 
exhaustive search for a causal gene in the linkage region on chromosome 10 was 
unsuccessful.55 Furthermore, whole genome SNP linkage analysis identified new linkage 
regions on chromosomes 1, 4 and 12, in addition to chromosome 10,55 but candidate gene 
analysis in the these regions was negative. As discussed in chapter 2, candidate gene 
analysis of the PLN gene was also negative.  
Recent research has shown that studying smaller variants alone is not sufficient to capture 
the full extent of meaningful genomic variation85 and larger genomic changes such as copy 
number variations (CNVs) may assist in the identification of causal variants. CNVs are 
duplications or deletions of DNA segments 1kb or larger in size and present in variable copy 
numbers in comparison to reference human genomes.86  A CNV may have a simple 
structure, such as tandem duplication, or may have a more complex involvement of gains or 
losses of homologous sequences at multiple sites in the genome.86 Thousands of CNVs have 
been described in the human genome to date, indicating that they contribute to genomic 
variation as much as single nucleotide polymorphisms (SNPs), short tandem repeats (STRs) 
and other small genetic changes.87 CNVs can encompass millions of DNA bases containing 
entire genes and their regulatory regions.87 Structural variations in certain genomic regions 
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may be benign and have no obvious phenotypic consequence or may be a  contributing 
factor to disease development.87 
CNVs contribute to disease development through a variety of mechanisms. One of the most 
common mechanisms is alteration of the copy number of a gene (or genes) or regulatory 
region sensitive to dosage effect.88 CNVs can also cause a position-dependent effect in the 
event of a translocation, even if the breakpoints are as far away as 1 megabase (Mb) from 
the causative gene.88 Another mechanism of disease for CNVs is the unmasking of recessive 
variants or functional polymorphisms of the remaining allele in the event of a deletion.88 
CNVs may have a similar effect on protein function and disease development as loss-of-
function variants in the case of a deletion, and may therefore play an important role in 
disease pathogenesis. 
CNVs have predominantly been associated with de novo complex disorders (e.g. autism and 
schizophrenia) and disease susceptibility (e.g. psoriasis, emphysema).88 There have also 
been reported cases of CNVs associated with Mendelian diseases, although they account for 
a minority of these cases in relation to other variant classes in most disease types.89-91 
However, CNVs are the major class of variants responsible for Mendelian conditions such as 
Duchenne muscular dystrophy, Charcot-Marie tooth disease, α-thalassemia and Prader-Willi 
syndrome.88 There are limited reports of involvement of CNVs in cardiovascular disease to 
date, with the majority of these reports focused on congenital heart diseases. Many 
reported CNVs overlap genes implicated in cardiovascular disease, such as RyR2 (ARVC), TTN 
(DCM) and KCNQ1 (Long QT syndrome).85 Losses in copy number in the desmosomal genes 
PKP2 and DSP, which are most commonly associated with ARVC, have been reported to 
cause this disease.92-94 Bearing this in mind, we elected to perform genome-wide CNV 
analysis to determine if there were any insertions, deletions or chromosomal 
rearrangements within the DNA segments of the ACM2 family that could account for the 
ARVC phenotype. Previous studies have identified CNVs in the desmosomal genes by 
multiplex ligation-dependent probe amplification (MLPA) or SNP genotyping arrays92-94, but 
this has a limited capacity for detection of CNVs as compared to the newer CytoScan® HD 
Array (Affymetrix) technology.  
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The CytoScan® HD Array is reported to have  the widest genomic coverage and best 
performance for the detection of human chromosomal aberrations.95 It can reliably detect 
25-50kb copy number variations throughout the genome at high specificity and >99% 
sensitivity.95 This array has >2.6 million copy number markers including 750 000 SNPs to 
enable accurate detection of changes in genomic copy number for accurate detection of 
breakpoint estimation, loss of heterozygosity (including copy-neutral loss of heterozygosity 
due to segment uniparental disomy), regions identical-by-descent, maternal contamination 
and low-level mosaicism.95 The simultaneous use of both probe sets allows validation of the 
results obtained by either of these probe sets. 
 
3.2. Objective 
The objective of this study was to determine if CNVs play a causal role in ARVC in the ACM2 
family. 
 
3.3. Specific aim 
- To screen for pathogenic CNVs in three members of the ACM2 family (2 affected 
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Individuals 2.4, 2.5 and 2.11 of the ACM2 family were screened for CNVs with the CytoScan® 
HD Array (Affymetrix). ACM2.4 and 2.5 are affected patients with ARVC while individual 2.11 
was unaffected, and was therefore used for exclusion of CNVs unlikely to play a role in the 
development of ARVC in the ACM2 family. 
 
3.4.1. ACM2 Family Evaluation 
ACM2 family members were evaluated as described in section 2.5.1.1. and classified as 
having definite, borderline or possible ARVC or being unaffected with this disease. 
 
3.4.2. DNA Isolation and Storage 
Sample DNA was isolated from blood samples and stored as described in section 2.5.2. 
 
3.4.3. Sample Quality Control – Concentration and Quality 
DNA sample concentration was determined using a PicoGreen® quantitation assay 
(Invitrogen). All DNA samples had the required concentration of >50ng/μl. 
 
3.4.4. Sample Quality Control – DNA Integrity 
All DNA samples were run on a 2% agarose gel to determine molecular weight and integrity. 
All samples were of sufficient molecular weight and free of degradation. 
 
3.4.5. Genomic DNA Preparation 
All samples were normalised to a concentration of 50ng/μl using Low EDTA TE buffer and 
250ng (5μl) of each sample was used in the CytoScan® assay. The Genomic DNA Control 
supplied in the CytoScan® Reagent Kit served as a positive control (concentration = 50ng/μl) 
to monitor assay performance, while low EDTA TE buffer provided with the CytoScan® 






3.4.6. Target Preparation 
3.4.6.1. Amplification 
Each sample was processed in accordance with the Affymetrix CytoScan® protocol. Samples 
were digested, ligated and subsequently amplified by PCR. Aliquots of the PCR product 
samples were run on a 2% gel to determine the success of the PCR as well as whether the 
PCR product generated was of the correct size (150-2000 bp). The PCR products were then 
purified and quantified. The required PCR product concentration is >300ng/μl for 
hybridisation to the array, and all samples met these quality control (QC) criteria. 
 
3.4.6.2. Fragmentation and labelling 
All samples were fragmented in accordance with the modified protocol provided by 
Affymetrix. An aliquot of each sample was run on a 4% gel to determine successful 
fragmentation of PCR products (distribution of fragmented samples should be 25-125 bp). 
All samples were successfully fragmented. The fragmented samples were subsequently 
labelled with a proprietary labelling reagent. 
 
3.4.7. Hybridisation 
Proprietary hybridisation buffers and an oligonucleotide control reagent were added to 
each sample to create a hybridisation cocktail. 200 μl of sample hybridization cocktail was 
injected into each array and the arrays were hybridised in an Affymetrix Hybridization Oven 
645 set at 50°C, 60 rpm for 17 hours. 
 
3.4.8. Washing, staining and scanning 
At the end of hybridisation, the arrays were washed and stained using the GeneChip® 










Following scanning, the CEL files generated by the Affymetrix Command Console® were 
analysed with the Affymetrix® Chromosome Analysis Suite (ChAS) (version 2.1.0.16). This 
software includes a quality control (QC) metric which identifies sample data that meet the 
required quality gates. The default QC threshold was used where: 
- SNP QC > 15  
- Median absolute pairwise difference (MAPD) <0.25 
- Waviness standard deviation (SD) <0.12 
Analysis was based on the reference genome sequence of the University of California, Santa 
Cruz (UCSC) Genome Browser hg19, February 2009 (GRCh37/hg19). Copy number variant 
analysis was performed using the ChAS software default filter settings which allowed 
detection of CNVs ≥400kb in size (marker count ≥ 50). Subsequent CNV analysis was 
conducted using the high resolution ChAS setting, which allowed detection of variants 
≥100kb in size (marker count ≥ 50). Final custom analysis settings allowed detection of all 
copy number variants ≥1kb in size (marker count ≥ 50). 
Variants were filtered according to presence in the Database of Genomic Variants96 
(http://dgv.tcag.ca/dgv/app/home), UCSC Genome Browser97 (https://genome.ucsc.edu/), 
DECIPHER database98 (https://decipher.sanger.ac.uk/) and the International Standards for 
Cytogenomic Arrays (ISCA) Consortium database (https://www.clinicalgenome.org/). 
 
3.5. Results 
The DNA samples of the three members (ACM2.4, ACM2.5 and ACM2.11) of the ACM2 
family passed all quality control measures. 
 
3.5.1. Analysis of CNV data using standard settings (CNVs ≥400kb) 
Analysis using the standard ChAS settings identified no variants of interest (common 






Figure 3.2: Genome-wide occurrence of regions with changes in copy number (≥400kb) in 
samples ACM2.4, 2.5 and 2.11. Chromosomes are listed from 1-12 (row 1) and 13-22, X and 
Y (row 2). Vertical lines (light blue, pink and purple) indicate characteristics of the different 
samples (green – 2.5, red – 2.4; purple – 2.11). Horizontal lines indicate regions showing 
losses (blue) and gains (red) in copy number. 
 
 
3.5.2. Analysis of CNV data using high resolution settings (CNVs ≥100kb) 
Analysis using this high resolution ChAS setting identified the ~201 kb CNV on chromosome 
14 (position 106,329,183 - 106,530,460), which was present in 3 copies in ACM2.4 and 2.5 
(Figure 3.3). This contains the KIAA0125 (RNA-coding) and ADAM6 (pseudogene) genes 
(Figure 3.4). This region was reported as highly variable in the Database of Genomic 






Figure 3.3: Genome-wide occurrence of regions with changes in copy number (≥100kb) in 
samples ACM2.4, 2.5 and 2.11. Chromosomes are listed from 1-12 (row 1) and 13-22, X and 
Y (row 2). Vertical lines (light blue, pink and purple) indicate characteristics of the different 
samples (light blue – 2.5, pink – 2.4; purple – 2.11). Horizontal lines indicate regions showing 





Figure 3.4: Region on chromosome 14 with CNV gain common between ACM2.4 and 2.5. 
Horizontal lines (light blue, pink and purple) indicate characteristics of the different samples 
(light blue – 2.5, pink – 2.4; purple – 2.11). Blue blocks indicate regions with a gain of copy 
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3.5.3. Analysis of CNV data using custom high resolution settings (CNVs ≥1kb) 
Analysis using the custom ChAS settings to detect CNVs ≥1kb identified one region on 
chromosome 17 which displayed a gain in copy number that was common to ACM2.4, 2.5 
and 2.11 (Figure 3.5); this was in addition to the region already reported in section 3.5.2. 
This region on chromosome 17 was ~62.9kb in size (position 44,225,439 - 44,288,296) and 
displayed a three copy gain in CNV across the KANSL1 and KANSL1-AS1 genes (Figure 3.6) in 
all three individuals. This region has been reported in the Database of Genomic Variants as it 




Figure 3.5: Genome-wide occurrence of regions with changes in copy number (≥1kb) in 
samples ACM2.4, 2.5 and 2.11. Chromosomes are listed from 1-12 (row 1) and 13-22, X and 
Y (row 2). Vertical lines (light blue, pink and purple) indicate characteristics of the different 
samples (light blue – 2.5, pink – 2.4; purple – 2.11). Horizontal lines indicate regions showing 






Figure 3.6: Region on chromosome 17 with CNV gain common between ACM2.4, 2.5 and 
2.11. Horizontal lines (light blue, pink and purple) indicate characteristics of the different 
samples (light blue – 2.5, pink – 2.4; purple – 2.11). Navy blocks indicate regions with a gain 
of copy number. Genes in the vicinity are indicated below the copy number losses.  
 
 
All variants were reported as part of larger pathogenic CNVs in the DECIPHER and ISCA 
databases. However, no pathogenic CNVs encompassing only regions defined by our CNV 




Analysis of data for ACM2.4, 2.5 and 2.11 obtained with the CytoScan® HD Array by 
standard settings revealed no CNVs of interest ≥400kb in size.  
Analysis with high resolution settings to detect CNVs ≥100kb in size identified a region on 
chromosome 14 that was present in 3 copies in ACM2.4 and 2.5. This region harbours the 
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KANSL1                                    ARL17B    NSFP1            ARL17A               NSF 
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reported in the Database of Genomic Variants as highly variable in many control individuals, 
and is therefore most likely a copy number polymorphism.  
Analysis with custom setting to detect all CNVs ≥1kb in size identified a region on 
chromosome 17 that displayed a copy gain across the KANSL1 and KANSL1-AS1 genes 
(Figure 3.6) in all three individuals (ACM2.4, 2.5 and 2.11). The KANSL1 gene has previously 
been implicated in 17q21.31 microdeletion syndrome (Koolen-de Vries syndrome)99,100 
which is characterised by hypotonia, highly distinctive facial features and moderate-to-
severe intellectual disability.99,100 Congenital cardiac defects have been reported in ~27% of 
cases, but this is not consistent with the phenotype observed in ARVC patients.101 Due to 
the role of this gene in histone acetylation and transcriptional regulation, and its previous 
association with syndromes which share no common phenotypical characteristics with 
ARVC, its role in the development of ARVC in the ACM2 family is unknown. The KANSL-AS1 
gene has no reported disease association to date. This region has been reported in the 
Database of Genomic Variants due to its presence in multiple control individuals, and is 
therefore very likely a copy number polymorphism. 
 
3.7. Conclusion 
We did not detect any chromosomal rearrangements or large CNVs that would account for 
the ARVC within this ACM2 family. It is therefore likely that the genetic cause of disease is 
either a point genetic variant or a small DNA deletion or insertion (most likely less <1kb in 
size). With the suspicion that we were looking for a small genetic variant, we elected to 












SCREENING BY EXOME SEQUENCING IN THE ACM2 FAMILY 
 
4.1. Introduction 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) has been attributed to variants in 
various genes, but the genetic factors responsible for the remaining ~50% of ARVC cases 
remain to be identified. As described in chapters 2 and 3, the main objective of this study 
was to identify the disease-causing genetic variant in the South African family (ACM2) with 
autosomal dominant ARVC (Figure 4.1). Extensive genetic analysis was previously performed 
using techniques such as whole genome single nucleotide polymorphism (SNP) linkage 
analysis, but no disease-causing variants were identified.44,55 As discussed in chapter 2, we 
performed candidate gene screening of the phospholamban gene (PLN), a newly identified 
cause of ARVC, but no disease-causing variants were identified in this family. We 
subsequently performed genome-wide copy number variant analysis but no significant 
change in copy number was seen which could account for the disease development in this 
family (chapter 3).  In previous work (PhD thesis of Mzwandile Mbele and MSc thesis of 
Maryam Fish) we had also screened this family for the five known desmosomal genes22,53 
but all screens were negative. We hypothesised that the disease-causing variant in this 
family was likely to reside in a gene that had not previously been associated with ARVC. 
Due to the dominant pattern of inheritance of this disease and the fact that 85% of disease-
causing variants lie within the exome,102 the possibility existed that the variant that we were 
looking for would also be found in the exome.  The advent of the whole exome sequencing 
(WES) technique in 2009 subsequently allowed us to use this approach to identify the causal 
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The objective of this study was to determine if a pathogenic exonic variant could be 
identified as the cause of ARVC in the ACM2 family. 
 
4.3. Specific aim 
- To perform whole exome sequencing of two members of the ACM2 family and 
screen for a disease-causing genetic  variant 
 
4.4. Methods 
Exome sequencing was performed in individuals ACM2.4 and 2.5 (Fig. 4.1) using two 
different methods – the SureSelect Human All Exon 50Mb kit (Agilent Technologies, Inc.) 
and the Ion AmpliSeq™ Exome Kit (Life Technologies). 
 
4.4.1. ACM2 Family Evaluation 
ACM2 family members were investigated at the Cardiac Clinic, Groote Schuur Hospital, Cape 
Town, and enrolled in the ARVC registry, and diagnosed according to the 2010 diagnostic 
criteria of ARVC15 as described in section 2.5.1.1.  
 
4.4.2. Control selection 
Controls were chosen from a South African population comprising anonymous blood 
donors. Self-reported ethnicity for these individuals was Caucasian. Informed consent was 
obtained from all participants (Appendix 1). 
 
4.4.3. DNA Isolation and Storage 
DNA was isolated and stored as described in section 2.5.2. 
 
4.4.4. Exome sequencing  
Two affected individuals from the ACM2 family (ACM2.4 and ACM2.5) were selected for 
exome sequencing using two different methods. For the first method, the SureSelect Human 
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All Exon 50Mb kit (Agilent Technologies, Inc.) was used and samples were sequenced with 
the Illumina HiSeq 2000. For the second method, the Ion AmpliSeq™ Exome Kit (Life 
Technologies) was used and samples were sequenced with the Ion Proton™ Sequencer (Life 
Technologies). Sequence analysis for this method was conducted using the Ion Reporter™ 
Software.  
We chose to perform two exome sequencing experiments for the following reasons: (1) the 
use of the newer Ion AmpliSeq™ Exome Kit (kit 2) would allow for detection of any genetic 
variation that was out of the range of the older SureSelect Human All Exon 50Mb kit (kit 1), 
as the newer kit provided more comprehensive exome coverage, (2) the results obtained 
with kit 2 would allow validation of the results obtained with kit 1 and (3) the experiment 
using kit 2 was run on a new, untested  next generation sequencing platform at Stellenbosch 
University, Cape Town. As the samples had previously been successfully sequenced with kit 
1 at another facility in Germany, we felt that the sequencing of these samples with the new 
system would validate the accuracy and efficiency of this system here in Cape Town, and 
would help with the establishment of next generation sequencing capacity in South Africa. 
 
4.4.4.1. SureSelect Human All Exon 50Mb kit 
For each of the two samples, 3µg of genomic DNA was analysed using the SureSelect Human 
All Exon 50Mb kit, which contains the exonic sequences for ~24 000 genes and covers 50Mb 
of genomic sequence.  
The exome sequencing process involves 3 steps: (1) DNA library preparation (section 
4.4.4.1.1.), (2) Cluster generation (library amplification) (section 4.4.4.1.2.) and (3) Sequence 
by synthesis (sequencing of the amplified library fragments) (section 4.4.4.1.3.). This 
experiment was performed at the Institute of Human Genetics, Helmholtz Zentrum 






4.4.4.1.1. DNA library preparation 
DNA samples were prepared using the Illumina Paired End Sample Preparation Kit (Illumina) 
and 50Mb SureSelect Human All Exon Capture kit (Agilent Technologies) according to 
instructions of the Illumina Paired End Sample Preparation Guide (Illumina). 
 
4.4.4.1.1.1. DNA quantification and fragmentation 
DNA sample concentrations were measured with the Qubit® fluorometer (Life Technologies) 
and the Qubit® dsDNA BR Assay Kit (Life Technologies) and NanoDrop 2000 
spectrophotometer (Thermo Scientific). DNA was then fragmented by the Covaris shearing 
method. Samples were purified with the QIAquick PCR Purification Kit (Qiagen), and samples 
were then concentrated to 30 µl with the Savant™ DNA SpeedVac™ Concentrator (Thermo 
Scientific). Concentrated DNA samples were then assessed with the Agilent 2100 
Bioanalyzer (Agilent Technologies) and the Agilent DNA 1000 Kit (Agilent Technologies). 
 
4.4.4.1.1.2. DNA library preparation 
4.4.4.1.1.2.1. End repair 
After DNA fragmentation by the Covaris method, the DNA fragments have 3’ and 5’ 
overhangs and blunt ends. End repair is conducted to convert all the overhanging fragments 
to blunt ends. End repair was performed with the Illumina Paired End Sample Preparation 
kit (Illumina). Samples were purified with the QIAquick PCR Purification Kit (Qiagen), and 
concentrated to 32 µl with the Savant™ DNA SpeedVac™ Concentrator (Thermo Scientific). 
 
4.4.4.1.1.2.2. Adenylation of 3’ ends 
Adenylation of fragments involved the addition of a single adenine nucleotide to the 3’ ends 
of the blunt fragments to prevent them from ligating to each other. A corresponding 
thymine nucleotide was added to the 3’ end of the adapter to provide a complimentary 
overhang that enables the adapter to ligate to the fragment. This was achieved with the 
addition of the Klenow fragment (3'→5' exo-) (New England Biolabs) according to the 
manufacturer’s instructions. Samples were then purified with the Qiagen MinElute PCR 
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Purification columns (Qiagen) and then concentrated to 10 µl with the Savant™ DNA 
SpeedVac™ Concentrator (Thermo Scientific). 
 
4.4.4.1.1.2.3. Paired end adapter ligation 
Adapters were ligated to all adenylated fragments with the Illumina Paired End Sample 
Preparation Kit (Illumina). Ligation reactions were purified with Agencourt AMPure XP beads 
(Beckman Coulter) and concentrated to 30 µl with the Savant™ DNA SpeedVac™ 
Concentrator (Thermo Scientific). 
 
4.4.4.1.1.3. PCR enrichment of paired end adapter ligated DNA fragments 
PCR was performed with the Illumina Paired End Sample Preparation Kit (Illumina). PCR 
products were purified with Agencourt AMPure XP beads (Beckman Coulter) and 
concentrated to 30 µl with the Savant™ DNA SpeedVac™ Concentrator (Thermo Scientific). 
After PCR purification and concentration, DNA fragment sizes were checked using an Agilent 
2100 Bioanalyzer (Agilent Technologies) and the Agilent DNA 1000 Kit (Agilent 
Technologies), in order to determine whether sizes differed from starting sizes after initial 
fragmentation. 500 ng of DNA is required for the exome enrichment step. 
 
4.4.4.1.1.4. Exome enrichment – hybridisation step 
Exome enrichment was performed with the 50Mb SureSelect Human All Exon Capture kit 
(Agilent Technologies) according to the manufacturer’s instructions. This procedure has 
three parts: 1) Preparation of the DNA capture plate, 2) Hybridisation buffer preparation 
and 3) Final library preparation. The end products of these three parts were combined to 
give a mixture of prepared library, baits and paired end blockers, which was then incubated 
in a thermal cycler for 24 hours at 65°C. After the 24 hour incubation, fragments that had 
not hybridised to the baits, i.e. non-exonic regions, were removed. RNA baits were then 





4.4.4.1.1.5. Post-hybridisation amplification 
After exome enrichment, library samples were amplified by PCR with the Illumina Paired 
End Sample Preparation Kit (Illumina). PCR products were purified with Agencourt AMPure 
XP beads (Beckman Coulter) and concentrated to 30 µl with the Savant™ DNA SpeedVac™ 
Concentrator (Thermo Scientific). 
 
4.4.4.1.1.6. Paired end library quantification 
The libraries were quantified using the 2100 Bioanalyzer (Agilent Technologies) and Agilent 
High Sensitivity DNA Kit (Agilent Technologies) before sequencing. 
 
4.4.4.1.2. Cluster generation 
Cluster generation involved the amplification of DNA libraries in an Illumina Flow Cell. The 
flow cell has eight lanes with each having a dense lawn of oligonucleotides attached to the 
inside surface which are complimentary to the paired end adapters flanking the gDNA 
libraries. The first step was denaturation of the libraries to single-stranded fragments at a 
set concentration, and then loading the denatured library in each lane to facilitate template 
hybridisation to the flow cell via the lawn of oligonucleotides. “Bridge PCR” was then 
performed, allowing fragments to be clonally amplified and several million clusters per lane 
to be generated. The reverse strands were then cleaved and washed away. The ends were 
blocked and the sequencing primer was hybridised to the DNA template, and the flow cell 
was then ready to load on the Illumina HiSeq 2000 sequencer for sequencing. 
 
4.4.4.1.3. Sequencing by synthesis 
After cluster generation, the flow cell was sequenced on the Illumina HiSeq 2000 sequencer 
with a 75 cycle Paired End protocol, which included 75 cycles of sequencing in the forward 
direction (termed Read 1) followed by 75 cycles in the reverse direction (termed Read 2). 





4.4.4.1.4. Data analysis 
4.4.4.1.4.1. Alignment and variant calling 
Reads were aligned against the human assembly hg19 (GRCh37) using Burrows-Wheeler 
Aligner (BWA v 0.7.5).   
Variant calling was performed using SAMtools (v0.1.19) and PINDEL (v0.2.4t). Variant quality 
was determined using the SAMtools varFilter script, using the default parameters (except 
for the setting of the minimum P-value for base quality bias to 1e-400). In addition, a 
custom script was applied to mark all variants having adjacent bases of low median base 
quality. All variants were then annotated using custom Perl scripts, including information 
about known transcripts (UCSC Known Genes and RefSeq genes), known variants (dbSNP 
v135), type of variant and, if applicable, amino acid change in the corresponding protein. 
 
4.4.4.1.4.2. Variant filtering 
The annotated variants were then inserted into the Helmholtz in-house database. All 
variants identified by exome sequencing were filtered according to a set of criteria. Genetic 
variants were verified in the 1000 Genomes project browser (www.1000genomes.org/), the 
Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.org) and 
internal Helmholtz database (5978 exomes).  
Predicted functional effect of non-synonymous variants was surveyed using PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph) and SIFT (http://sift.jcvi.org/). 
To identify putative disease-causing variants, the Helmholtz database was queried to show 
only variants identified in both affected subjects. To reduce false positives, variants that had 
a variant quality of less than 30 were excluded. As an internal frequency filter, only variants 
present in less than 4 internal controls were considered. All synonymous and intronic (other 
than canonical splice site) variants were excluded. 
The raw read data of the variants identified was then manually investigated using the 





4.4.4.2. Exome Sequencing with the Ion AmpliSeq™ Exome Kit 
The Ion AmpliSeq™ Exome Kit includes 294,000 primer pairs that amplify the whole exome 
in 12 primer pools using as little as 50 ng of DNA. Sample DNA was amplified using the Ion 
AmpliSeq™ Exome Kit and sequencing was performed with the Ion Proton™ Sequencer and 
the Ion PI™ Chip Kit v2 (Life Technologies) according to the manufacturer’s instructions. This 
experiment was performed at the Central Analytical Facilities Sequencing Lab at 
Stellenbosch University. Data analysis was performed with the assistance of Dr Guillaume 
Pare at McMaster University in Toronto, Canada. 
 
4.4.4.2.1. Exome sequencing method 
A total of 100 ng of genomic DNA per sample was amplified using the Ion Ampliseq™ Exome 
Primer Panel (Life Technologies) (part of the Ion AmpliSeq™ Exome Kit (Life Technologies)). 
DNA quantification and quality assessment was performed with the Qubit™ 2.0 Fluorometer 
(Life Technologies) and the Qubit® dsDNA HS Assay Kit (Life Technologies). Amplification 
was performed using a Veriti® Thermal Cycler (Life Technologies) using the following cycling 
conditions: an activation step at 99°C for 2 min followed by 10 cycles of 99°C for 15 sec and 
60°C for 16 min. 
The library was then prepared with the Ion AmpliSeq™ Library Kit V2 (Life Technologies) and 
Ion Xpress™ Barcode Adapters (Life Technologies). In short: the 12 individual reaction 
products were pooled and the primers were digested using the supplied FuPa reagent (Life 
Technologies). This was followed by adapter ligation during which the barcodes were added. 
The post-ligation products were purified using Agencourt AMPure XP reagent (Beckman 
Coulter) after which the products were amplified by limited PCR. Amplification was done 
with a Veriti® Thermal Cycler (Life Technologies) as follows: an activation step at 98°C for 2 
min was followed by 5 cycles of 98°C for 15 sec and 64°C for 1 min. The amplified library was 
then purified with Agencourt AMPure XP reagent (Beckman Coulter). The libraries were 
quantified using real time PCR with the Ion Library Quantitation Kit (Life Technologies) using 
a StepOnePlus™ Real-Time PCR System (Life Technologies). The libraries were normalised to 
100 pM and pooled in equal volumes prior to template preparation on the Ion OneTouch™ 2 
System (Life Technologies) with the Ion PI™ Template OT2 200 Kit v2 (Life Technologies). 
Enrichment and purification of the Ion Sphere Particles (ISPs) was performed on the Ion 
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OneTouch™ ES (Life Technologies) using the Ion PI™ Template OT2 200 Kit v2 (Life 
Technologies). The enriched ISPs were analysed on the Ion Proton™ System (Life 
Technologies) using the Ion PI™ Sequencing 200 Kit v2 (Life Technologies) and the Ion PI™ 
Chip v2 Kit (Life Technologies). Data was collected and analysed using the Torrent Server 
with Torrent Suite Version 4.0.2 (Life Technologies). 
 
4.4.4.3. Validation of potentially disease-causing variants 
The shortlisted variants were then validated with high resolution melt analysis and Sanger 
sequencing. All available ACM2 family members (affected and unaffected) were screened 
for the shortlisted variants in order to determine segregation of these variants with disease. 
Variants were then assessed using various bioinformatic tools in order to determine if they 
were likely to affect mRNA splicing, mRNA secondary structure or protein function as 
described in section 2.5.7. 
 
4.4.5. HRM Analysis 
HRM analysis was used to screen for the variants of interest in the entire ACM2 family to 
determine whether or not these variants segregated with disease in the family. This 
technique was also used to screen 100 Caucasian controls (200 chromosomes) for the 
variants of interest identified by exome sequencing. The samples of interest were compared 
to samples known to be positive for the variants of interest, namely ACM2.4 and ACM2.5. 
Primers were designed according to criteria described in section 2.5.4.1. to amplify the 
regions surrounding the variants identified by exome sequencing. The primers used for the 
combined real-time PCR and HRM of the genes of interest are shown in Table 4.1, while the 
reagents are shown in Table 4.2 and the reaction conditions in Table 4.3.  
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Table 4.1: Primers for the PCR and HRM of the variants of interest 
 




ADD1_F CCA CAG CTC CTA CCA TAT CCT TC 23 52.2 56.6 
273 c.1810C>G; p.Q604E 
ADD1_R GAA AGG TGT CAC GTC CTG GC 20 60 58.5 
ANKRD62_F ATG ACT AAT ATG ACA GAC TGA G 22 36.4 49.1 
285 c.1071-1073delATA 
ANKRD62_R ACC TAT CAA ACT CGC CAT TC 20 45 52.5 
ASCL1_F TTT TTA ACT TCC GTC AGG GCT C 22 45.5 55.3 
451 c.86C>T; p.A29V 
ASCL1_R GTT TGC AGC GCA TCA GTT CGG 21 57.1 59.7 
B3GNT6_F CGC ACA GCA GTC CTC CTT C 19 63.2 58.4 
194 c.1073G>A; p.R358H 
B3GNT6_R TTC TCA GCA TGG ACA TGG TTG 21 47.6 55.4 
BDH2_F ATC ATG GAA CTG TCC TGG 18 50 51.5 
135 c.326T>C; p.M109T 
BDH2_R CAG TAC AGA GAC CTA ATG TGG TG 23 47.8 54.6 
BRCA1_F TTG GAA CCA GGT TTT TGT G 19 42.1 51 
154 c.4132T>C; p.I1378V 
BRCA1_R TCT ATG AAA AGC ACC TTA GGA G 22 40.9 51.9 
C15orf62_F ACC ACG AGG AGT ACA GCA AC 20 55 56.9 
225 c.217_delCG; p.R73fs 
C15orf62_R ACA GAG AGA GCG CCG ATG 18 61.1 57.2 
C17orf80_F CGT GTG GGA GCA AAG GAA ATG 21 52.4 56.8 
184 c.1007A>C; p.N336T 
C17orf80_R GAA TGA AAC TGG TAA GTC GTC 21 42.9 51.1 
CAMK4_F TGT TTC CAA TCA GGC AGC GG 20 55 58.4 
230 c.1110A>C; p.K370N 
CAMK4_R AGG CTT GCA CCT TCA TCA GCT C 22 54.5 59.9 
CDH2_F GAT AAA AAC CTT TCA CTG CGG 21 42.9 52.2 
241 c.686A>C; p.Q229P 
CDH2_R TCA GTA TTG AGG CTT TCA GAC 21 42.9 52.1 
CFHR2_F GTA TAT GCT CCA GGT TCA TC 20 45 50.1 
173 c.595G>T; p.E199X 
CFHR2_R AAT ATC AGA CTC ATC ACA CTG 21 28.1 49.5 
CLTC_F GAC AGA ACT GAT ATT CGC AC 20 45 51 
145 c.3568A>G; p.I1190V 
CLTC_R CAA GCT AAT CAA GTA GCC C 19 47.4 50.5 
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DDX56_F GGC CAG ACC AGT TAC AGC AG 20 60 58.1 
250 c.824G>A; p.R275H
DDX56_R CTT CAA CTT ATT TCA ACC AAG ATG 24 33.3 50.5 
DSG1_F GTT AGC CAA TGC CCA CAA TG 20 50 54.7 
169 c.2914G>A; p.G972S
DSG1_R CAC TTA TGC CAG CTC CAC TC 20 55 55.6 
DUSP18_F GCC CAT CAT CCG ACC CAA C 19 63.2 58.8 
195 c.490_delTG; p.V164fs
DUSP18_R ATC TGT ACC TCT GAC TCC AAT G 22 45.5 53.7 
ENPP7_F ACA GGT ACG GCC CCG AGT C 19 68.4 61.8 
167 c.712C>A; p.R238S
ENPP7_R GTC GCC AGC CCG TTT GTC 18 66.7 59.7 
EP400_F CCT CTC CAG GCT TCC AGT TC 20 60 57.4 
255 c.442C>A; p.Q148K
EP400_R GAG GGG CTC AAG CTG ATC TG 20 60 57.7 
ESCO1_F TCA AAA ATG GCT ACT TCA GTG G 22 40.9 53.3 
160 c.826C>G; p.L276V
ESCO1_R TAC CTC GTT TGC TCT TTC CTG 21 47.6 54.7 
FSCN3_F CCA TCC AGA TAA CTC CTT CC 20 50 52.1 
180 c.1181G>A; p.R394H
FSCN3_R CGG CAG GGT AGT AGA TGA ATG 21 52.4 54.9 
G6PC_F GTT GGG ATT CTG GGC TGT G 19 57.9 56.2 
172 c.558G>T; p.L186
G6PC_R CTG GGA TTT TGT CCT GAT TAG 21 42.9 50.8 
GALNT2_F GAG CTG GTG GTC ATG TGC AG 20 60 58.6 
159 c.1333A>G; p.I445V
GALNT2_R TGA CAT TCA TAA ACT CCA ACC 21 38.1 50.4 
HTR3C_F CAT GGA TGT GGA TCA GAC GCC 21 57.1 58.1 
241 c.556A>G; p.T186A
HTR3C_R TCT AAT GAT ACC TAC ACC ACT C 22 40.9 50.9 
KIF21B_F GTC GGC CAG CAC TAC CTC ATC 21 61.9 59.9 
143 c.2641T>A; p.L881M
KIF21B_R CTT ACC GGG CAG GAC GGG 18 72.2 60.9 
KLF11_F AGG GGA GAA GAA GTT TGT GTG 21 47.6 54.7 
224 c.1430T>G; p.M477R
KLF11_R AAA TCC CAT GAG TGA TGT CC 20 45 52.3 
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Table 4.1: Primers for the PCR and HRM of the variants of interest (continued) 
 




KRT17_F TGG AGG CCG ACA TCA ATG G 19 57.9 57.6 
223 c.667C>T; p.E223K 
KRT17_R CCT GCT CTG CTC TCT CCC AC 20 65 57.9 
KRT31_F CTT GAC CCA GGC ATT CTT AC 20 50 53.3 
249 c.1151C>T; p.P384L 
KRT31_R TAG CGC ACG AAG GAA TTG 18 50 52.9 
KRT34_F ATT CCA ACT AAC TCC AGC C 19 47.4 52 
327 c.1256C>T; p.A419V 
KRT34_R AAA TAA CAT AGA GGC AAG ATG AG 23 34.8 50.5 
KRTAP9-2_F CTG GAA GCC CAC CAC TGT G 19 63.2 58.6 
300 c.250C>A; p.P84T 
KRTAP9-2_R GG TAG TAG CAG GTT CTT C 19 52.6 52 
KRTAP16-1_F AGC CAC CTC TCT CTG CTC CAC 21 61.9 61 
329 c.217A>G; p.C73R 
KRTAP16-1_R AGC AAG AAG GCT CAC AGA TG 20 50 55 
LAMC2_F GAC AAG GGA GGC CAC TCA AG 20 60 57.9 
218 c.2570G>C; p.R857P 
LAMC2_R CAA CAT GGA GAA AAA GCT GAA TG 23 33.1 52.9 
MYO16_F TCC TCT CTG TTG TTT TCA GTG 21 42.9 52.9 
240 c.334G>A; p.V112I 
MYO16_R TGC AGC TTA TCA TCC AAG CCT G 22 50 57.6 
NCOA3_F GAG AGC TGC TAA GTC ATC AC 20 50 52.7 
241 c.T3729del-GCAGCAGCA; p.M1243delQQ? 
NCOA3_R TTG GTT GAT ATG GAA ACT GTT G 22 36.4 51.2 
NEK10_F GTT ATG GAG CTG ATA GAA GGA G 22 45.5 52.2 
189 c.1889G>A; p.R630K 
NEK10_R CCA AAG ATG ACT ACT GCA CGT C 22 50 55.7 
OR4D6_F TGA TCT CTA ACA ACG GAC TG 20 45 51.5 
173 c.665T>C; p.L222P 
OR4D6_R GTA AAC ACA AGG CAC GAA G 19 47.4 51.6 
RTL1_F GAA CCT GAC CTG GAT CGA CTC 21 57.1 57 
124 c.1195G>A; p.E399K 
RTL1_R GTT CAC TCT CAC CAT GAG 18 50 49.7 
SCN4A_F GAG TCC CTC ATC AAG ATA CTG 21 47.6 51.9 
274 c.606G>C; p.M202I 
SCN4A_R GAG AGT GCT GAG CCA GAC 18 61.1 55.2 
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Table 4.1: Primers for the PCR and HRM of the variants of interest (continued) 
 




TTC37_F GAG TCA CAA AAG CCA CTC CCA G 22 54.5 58.1 
244 c.4187A>G; p.N1396S 
TTC37_R TAG TTC CTC TAA CCA CAA TAC C 22 40.9 51.3 
ZGRF1_F CCC AGG TTC CAC TTA TTA CTT TG 23 43.5 53.5 
157 c.3256A>G; p.M1086V 
ZGRF1_R AAG AAC TGC TGA CTT TTC ACA C 22 40.9 53.6 
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Table 4.2: Reagents for the PCR and HRM of the variants of interest 
REAGENT (STOCK CONCENTRATION) 
FINAL CONCENTRATION / VOLUME PER 
REACTION 
Forward Primer (20 µM) 0.8 µM / 0.5 µl 
Reverse Primer (20 µM) 0.8 µM /0.5 µl 
dNTPs (20 µM) (Bioline ) 0.8 µM / 1 µl 
GoTaq Polymerase (5U/ ul ) (Promega) 0.5 U / 0.1 µl 
GoTaq FlexiBuffer (5X) (Promega) 1 X / 5 µl 
MgCl2 (25 mM) (Promega) 1.5 mM / 3 µl 
EvaGreen dye (Anatech) 1X / 1 µl 
DNA 200 ng 
FINAL REACTION VOLUME 25 µl 
 
 












For the screening of the ACM2 family, the HRM amplicons for all family members were 
subjected to Sanger sequencing to confirm the presence of the variants of interest. For the 
population control screening, any sample that displayed a similar HRM profile to the 
positive control from the ACM2 family was subjected to Sanger sequencing to confirm the 






CONDITION TEMPERATURE (TIME) 




95°C – 5 seconds 
                    55°C – 10 seconds      50 cycles 
72°C – 10 seconds 
High Resolution Melt 





4.5.1. Sample characteristics 
The ACM2 samples (ACM2.4 and ACM2.5) are described in Table 4.4.  Five individuals (the 
proband (Individual III:3 for whom we did not have DNA), ACM2.2 (Figure 4.1, III:10), 
ACM2.4 (Figure 4.1, III:6), ACM2.5 (Figure 4.1, III:5) and ACM2.12 (Figure 4.1, II:4)) fulfilled 
the criteria for definite ARVC while one individual (ACM2.9 – Figure 4.1, II:8) fulfilled criteria 
for borderline ARVC.15 The control population consisted of 100 healthy Caucasian individuals 
(200 chromosomes). 
 
4.5.2. Exome sequencing output 
Exome sequencing of ACM2.4 and ACM2.5 was performed with the SureSelect Human All 
Exon 50Mb kit (Agilent Technologies, Inc.) and run on the Illumina HiSeq 2000. For ACM2.4, 
the average coverage depth was 199.8 and 20x coverage for 92.16% of the target bases, 
while for ACM2.5, the average coverage depth was 204.8 and 20x coverage for 92.06% of 
the target bases (Table 4.5). 
Exome sequencing of these samples was also performed with the Ion AmpliSeq™ Exome Kit 
(Life Technologies) and samples were run on the Ion Proton™ Sequencer (Life Technologies). 
For ACM2.4, the average coverage depth was 129.9 and 5x coverage for 93.21% of the 
target bases, while for ACM2.5, the average coverage depth was 121.4 and 5x coverage for 
93.91% of the target bases (Table 4.5). 
After bioinformatic analysis of data from both exome sequencing experiments, a number of 
variants common between ACM2.4 and ACM2.5 were highlighted. A search was then 
conducted in various genetic variation databases to determine the novelty and prevalence 
of these variants. These include the 1000 Genomes database 
(http://browser.1000genomes.org/index.html), the Exome Aggregation Consortium (ExAC) 
database as well as a database of in-house control exomes. 
4.5.2.1. Variants identified with the SureSelect Human All Exon 50Mb kit 
These variants included 21 missense variants and 1 synonymous variant (22 variants in total) 
(Table 4.6 and Figure 4.2a). Of these variants, 9 were detected on chromosome 17 with 
many other variants found on chromosomes 18 (n = 4) and 11 (n = 2) (Figure 4.3a).
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Arrhythmias Diagnostic criteria Outcome 
Proband IV: 5 M 15 
Palpitations 
with sweating 




No information TWI V1-V5 
Epsilon wave 
TAD >55ms 
VT (LBBB with 
superior axis) 
DEFINITE ARVC 
4 major, 1 minor 
Died (age 21) 

























2 major, 1 minor 
No 
information 
ACM2.3 III:14 M 45 Asymptomatic 
Normal 
echocardiogram 
No information No TWI No information No information UNAFFECTED 
No 
information 
































ACM2.5 IV:7 F 
No 
information 



























Arrhythmias Diagnostic criteria Outcome 
ACM2.6 III:17 F 
No 
information 
No information No information No information No information No information No information No information 
No 
information 
ACM2.7 II:17 F 75 No information No information No information No information No information No information No information 
No 
information 
ACM2.8 IV:3 M 44 Asymptomatic 
MRI: Focal area of 
dyskinesia RVOT 
but did not fulfil 

















Holter normal UNAFFECTED 
No 
information 





MRI reported as 
normal 





No holter done 
EST normal 
BORDERLINE ARVC 
1 majot, 1 minor 
No 
information 
ACM2.10 IV:16 M 27 Asymptomatic 













NSVT on Holter 




























Arrhythmias Diagnostic criteria Outcome 
ACM2.11 IV:17 F 21 
Palpitations, 
chest pain, 
episode of near 
syncope 




No information No TWI 
No epsilon 
wave 





2009 and 2014 
EST normal 
No holter done 

















No holter done 





ACM2.13 III:18 M 43 Asymptomatic No information No information No information No information No information No information 
No 
information 
ACM2.14 V:3 F 11 Chest pain No information No information No information No information No reported VT No information 
No 
information 
ACM2.15 V:2 F 2 No information No information No information No information No information No information No information 
No 
information 























Arrhythmias Diagnostic criteria Outcome 
ACM2.17 IV:4 F 34 No information No information No information No information No information No information UNAFFECTED 
No 
information 
ACM2.18 IV:14 F 19 No information No information No information No information No information No information No information 
No 
information 
ACM2.19 III:16 M 53 No information No information No information No information No information No information UNAFFECTED 
No 
information 








M – Male; F – Female; RV – Right ventricle; RVA – Right ventricular akinesia; TWI – T-wave inversion; TAD – Terminal activation duration; VT – Ventricular tachycardia; LBBB – Left bundle branch block; PVC – Premature 
ventricular contractions; EPS – Electrophysiological study; NSVT – Non-sustained ventricular tachycardia; MRI – Magnetic resonance imaging; EMB – Endomyocardial biopsy; EST – Exercise stress test; RVIT – Right 
ventricular inflow tract; ICD – Implantable cardioverter defibrillator; RVOT – Right ventricular outflow tract; SAECG – Signal-averaged electrocardiogram 
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Table 4.5: Exome sequencing results overview 
 SureSelect Human All Exon 50 Mb kit Ion AmpliSeq™ Exome Kit 
 ACM 2.4 ACM 2.5 ACM 2.4 ACM 2.5 
Total variants called 
Off target variants are 
not called 
76.5% reads on target 
Off target variants are 
not called 
76.0% reads on target 
49996 49590 
Total variants on target 76400 72102 49006 48658 
Coverage 199.8X; 92.16% @ 20X 204.5X;  92.06% @20X 129.9X; 93.21% @ 5X 121.4X; 93.9% @ 5X 
Transition/transversion ratio 2.47 2.52 3.12 3.16 
Variants present in the 1000Genomes database 58433 57707 45234 44843 
Variants present in the dbSNP database 60354 59603 47471 47158 







 Non-frameshift Insertion/deletion 
 Splice 
 5’ UTR 

















































4.5.2.2. Variants identified with the Ion AmpliSeq™ Exome Kit  
These variants included 23 missense variants, 1 synonymous variant, 2 frameshift variants, 1 
non-frameshift deletion and 1 nonsense variant (Table 4.7 and Figure 4.2b). Six of these 
variants were found on chromosome 17 and many other variants were also detected on 
chromosomes 1 (n = 4) and 4 (n = 3) (Figure 4.3b).  
 
Table 4.6: Variants identified with the SureSelect Human All Exon 50Mb kit 
CHR GENE VARIANT TYPE 
1 GALNT2 c.1333A>G; p.I445V Missense 
2 KLF11 c.1430T>G; p.M477R Missense 
3 NEK10 c.1889G>A; p.R630K Missense 
4 ADD1 c.1810C>G; p.Q604E Missense 
7 FSCN3 c.1181G>A; p.R394H Missense 
11 OR4D6 c.665T>C; p.L222P Missense 
11 B3GNT6 c.1073G>A; p.R358H Missense 
12 EP400 c.442C>A; p.Q148K Missense 
13 MYO16 c.268G>A; p.V90I Missense 
17 KRTAP9-2 c.250C>A; p.P84T Missense 
17 KRTAP16-1 c.217A>G; p.C73R Missense 
17 KRT34 c.1256C>T; p.A419V Missense 
17 KRT31 c.1151C>T; p.P384L Missense 
17 KRT17 c.667C>T; p.E223K Missense 
17 G6PC c.558G>T; p.L186 Synonymous 
17 BRCA1 c.4132T>C; p.I1378V Missense 
17 CLTC c.3568A>G; p.I1190V Missense 
17 SCN4A c.606G>C; p.M202I Missense 
18 ANKRD62 c.1071_1073delATA Missense 
18 ESCO1 c.826G>C; p.L276V Missense 
18 CDH2 c.686A>C; p.Q229P Missense 









Table 4.7: Variants identified with the Ion AmpliSeq™ Exome Kit 
CHR GENE VARIANT TYPE 
1 LAMC2 c.2570G>C; p.R857P Missense 
1 CFHR2 c.595G>T; p.E199X Stop 
1 KIF21B c.2641T>A; p.L881M Missense 
1 GALNT2 c.1333A>G; p.I445V Missense 
2 KLF11 c.1430T>G; p.M477R Missense 
3 NEK10 c.1889G>A; p.R630K Missense 
3 HTR3C c.556A>G; p.T186A Missense 
4 ADD1 c.1810C>G; p.Q604E Missense 
4 BDH2 c.326T>C; p.M109T Missense 
4 ZGRF1 c.3256A>G; p.M1086V Missense 
5 TTC37 c.4187A>G; p.N1396S Missense 
5 CAMK4 c.1110A>C; p.K370N Missense 
7 DDX56 c.824G>A; p.R275H Missense 
7 FSCN3 c.1181G>A; p.R394H Missense 
12 ASCL1 c.86C>T; p.A29V Missense 
13 MYO16 c.334G>A; p.V112I Missense 
14 RTL1 c.1195G>A; p.E399K Missense 
15 C15orf62 c.217_delCG; p.R73fs Frameshift 
17 KRT34 c.1256C>T; p.A419V Missense 
17 KRT31 c.1151C>T; p.P384L Missense 
17 G6PC c.558G>T; p.L186 Synonymous 
17 CLTC c.3568A>G; p.I1190V Missense 
17 C17orf80 c.1007A>C; p.N336T Missense 
17 ENPP7 c.712C>A; p.R238S Missense 
18 ESCO1 c.826C>G; p.L276V Missense 























Figure 4.3: Variant distribution by chromosome – SureSelect (A) and Ion AmpliSeq™ (B) 
Exome Sequencing Experiments 
 
The combination of the variant data from both exome sequencing experiments revealed a 
list of 12 variants common to the two datasets (Table 4.8). A significant amount of variant 
overlap was expected, as the same two samples were sequenced in both experiments. The 
differences in variant lists obtained with these experiments could be due to differences in 





sequencing kits, as well as variations in the variant calling and filtering criteria, as has been 
reported previously.103 Follow-up experiments were performed for all variants, irrespective 
of whether the variant was detected by one or both kits. 
 
Table 4.8: Variants common between the SureSelect and Ion AmpliSeq™ Exome Sequencing 
Experiments 
CHR GENE VARIANT TYPE 
1 GALNT2 c.1333A>G; p.I445V Missense 
2 KLF11 c.1430T>G; p.M477R Missense 
3 NEK10 c.1889G>A; p.R630K Missense 
4 ADD1 c.1810C>G; p.Q604E Missense 
7 FSCN3 c.1181G>A; p.R394H Missense 
13 MYO16 c.334G>A; p.V112I Missense 
17 KRT34 c.1256C>T; p.A419V Missense 
17 KRT31 c.1151C>T; p.P384L Missense 
17 G6PC c.558G>T; p.L186 Synonymous 
17 CLTC c.3568A>G; p.I1190V Missense 
18 ESCO1 c.826G>C; p.L276V Missense 
18 CDH2 c.686A>C; p.Q229P Missense 
 
 
The entire ACM2 family (affected and unaffected individuals) was then screened for these 
variants to determine their segregation with disease. The variants were also subjected to 
population screens in 200 ethnically matched (Caucasian) control chromosomes. The 
RNAfold and Mfold bioinformatic analysis tools were used to predict whether these three 
variants caused structural mRNA changes, while the ESEFinder tool was used to predict 
whether variants affected mRNA splicing, by determining whether variants affected exonic 
splice enhancers (ESEs). The MutationTaster, Mutation Assessor, Polyphen-2, SIFT and Align 
GVGD bioinformatic tools were used to determine whether these variants had a deleterious 





Variants were filtered according to the following criteria (Figure 4.4): 
(1) Presence in all affected individuals. We did not exclude variants detected in 
individuals classified as unaffected due to possible incomplete penetrance. 
(2) Absence in the control population. Variants found to be present in  ≥1% of the 
control population were excluded 
(3) Amino Acids need to be conserved across multiple species 
(4) Prediction of pathogenicity by bioinformatic tools 
(5) The affected gene is a functionally plausible ARVC candidate 
After filtering according to criteria 1 to 4 listed above, the list of candidate variants included 
the KIF21B c.2641T>A (p.L881M), TTC37 c.4187A>G (p.N1396S) and CDH2 c.686A>C 
(p.Q229P) variants. KIF21B encodes the Kinesin Family Member 21B protein which is known 
to play a role in neuronal component transport.104 The TTC37 gene encodes the 
Tetratricopeptide Repeat Domain 37 protein which is known to be involved in exosomal 
RNA degradation.105 The CDH2 gene encodes the N-cadherin protein which plays an 
important role in cell adhesion and is known to interact with proteins previously implicated 
in ARVC,106 making it the most functionally plausible candidate gene for this disease. Based 





Figure 4.4: Filtering of exome sequencing variants 
PRESENT IN ALL AFFECTED INDIVIDUALS & 
ABSENT IN THE CONTROL POPULATION 
TOTAL VARIANTS COMMON BETWEEN 
ACM2.4 AND 2.5 (BOTH EXPERIMENTS)  
AFFECTING CONSERVED AMINO ACIDS 
BIOINFORMATICALLY PREDICTED TO BE 
DELETERIOUS 
NOT FOUND IN >1 ACM2 MEMBER WITH 
UNAFFECTED/ UNCHARACTERISED 
PHENOTYPE 
BIOLOGICALLY PLAUSIBLE CANDIDATE GENE 
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4.5.2.3. CDH2 c.686A>C (p.Q229P) 
This variant was found in all affected individuals (definite and borderline ARVC) (Figure 4.6), 
and was not detected in the South African Caucasian control population. This variant is 
conserved across multiple species (Figure 4.5), and was not reported in the 1000 Genomes, 
NHLBI Exome Variant Server, NCBI dbSNP and ExAC databases or the Helmholtz in-house 










Figure 4.5: Identification and conservation of the CDH2 c.686A>C (p.Q229P) variant. (A) 






H. sapiens    218 QLSVTKPLDREQIARFHLRAHAVD 241 
P. troglodytes   218 QLSVTKPLDREQIARFHLRAHAV 240 
M. mulatta    201 QLSVTKPLDREQIARFHLRAHAV 223 
G. gallus    223 QLSVTKPLDREQIASFHL  240 











2.12 2.6 2.92.3 2.19 2.13
2.8 2.52.17 2.4 2.1 2.22.20 2.18 2.10 2.11
2.16 2.15 2.14
            CDH2 c.686A>C; p.Q229P 







Bioinformatic tools (Mfold and RNAFold) predicted that the CDH2 c.686A>C variant would 
alter mRNA secondary structure (Figure 4.7), and would cause a change in SRSF1 recognition 
sites (Figure 4.8). This variant was also predicted to have a deleterious effect on protein 
function by the MutationTaster, Polyphen-2, SIFT and Align GVGD bioinformatic tools. There 
are therefore many lines of bioinformatic evidence that suggest the deleterious effect of 
this variant. 
 
                           
 
        
Figure 4.7: Mfold and RNAfold predictions for the CDH2 c.686A>C variant. (A) Mfold wild type 







       
        
Figure 4.8: ESEFinder predictions for the CDH2 c.686A>C variant. (A) ESEFinder prediction 
for wild type sequence; (B) ESEfinder prediction for mutant sequence 
 
Based on the fact that the CDH2 c.686A>C (p.Q229P) variant (1) is detected in all affected 
individuals in the ACM2 family, (2) alters a conserved amino acid, (3) is absent in 200 
ethnically matched control chromosomes, (4) was not reported in the 1000 Genomes, 
Exome Variant Server, NCBI dbSNP or ExAC databases, (5) is bioinformatically predicted to 
be deleterious by various predictive tools and (6) is a biologically plausible candidate  (based 
on the role of N-cadherin in the cell), we classify this variant as a possibly disease-associated 
variant. This evidence suggests that this variant may play a causal role in the development 
of ARVC in the ACM2 family. 
  SF2/ASF  
  SF2/ASF (IgM-BRCA1)  
  SC35  
  SRp40  






By combining the information gathered from two whole exome sequencing experiments we 
believe we have not only identified CDH2 as the causative gene within this family but we 
have also identified CDH2 as a new candidate gene for ARVC and cardiomyopathy in 
general. 
Based on genetic and bioinformatic evidence, the most likely disease-causing variant in the 
ACM2 family is the CDH2 c.686A>C (p.Q229P) variant. This variant segregates with disease 
within this family, is absent in the control population and control databases and is 
bioinformatically predicted to have a deleterious effect on the function of CDH2. 
Functionally, the CDH2 gene encodes the N-cadherin protein, which is a member of the 
cadherin superfamily of predominantly calcium-dependent cell adhesion proteins.107 N-
cadherin is comprised of five extracellular cadherin repeats, a transmembrane region and a 
highly conserved cytoplasmic tail (Figure 4.9).108 The cadherin repeats are vital for the 
adhesive function of N-cadherin.  Calcium ions bind to each cadherin repeat to ensure 
correct protein folding and confer rigidity to the extracellular domain. Multiple cadherin 
domains form Ca2+-dependent rod-like structures with conserved Ca2+-binding pockets at 
the inter-domain region.109 The p.Q229P variant is located in cadherin repeat 1, and it is 
therefore plausible that this variant would affect the adhesive function of the N-cadherin 
protein. 
Members of the cadherin superfamily have distinct spatial and temporal expression 
patterns during embryonic development and adulthood.110 Changes in cadherin expression 
are often associated with changes in tissue architecture and cell morphology.110 In the 
heart, N-cadherin is located at the intercalated disc and forms part of the adherens junction 
where it co-localises with the desmosomal proteins known to play a role in the development 
of ARVC.106 N-cadherin has been shown to associate directly with plakoglobin, one of the 
proteins found in the desmosome.111 Although the main role of N-cadherin is cell adhesion, 




Figure 4.9: Position of the c.686A>C (p.Q229P) variant in the CDH2 protein 
 
Several CDH2 mouse models have been developed. CDH2 knockout mice died in the 
embryonic stage due to a severe cardiac defect.110 Induced cardiac-specific deletion of N-
cadherin in the mouse heart caused dissolution of the intercalated disc structure including 
desmosomes and adherens junctions106, an observation which is similar to what is seen in 
individuals with ARVC. These mice also exhibited dilated cardiomyopathy and the abrupt 
onset of ventricular tachycardia, providing evidence that the deaths were arrhythmic in 
nature.106 Mice with N-cadherin haploinsufficiency exhibited a reduction in Connexin-43 
plaque size in the myocardium as well as increased susceptibility to arrhythmias, indicating 
that N-cadherin influences gap junction function.114 
N-cadherin is also known to interact directly with components of the Wnt/β-catenin and 
Hippo signalling pathways known to be involved in ARVC.33 It is therefore plausible that 
variants in CDH2 could lead to the development of ARVC by disruption of the intercalated 
disc structure and modulation of the Wnt/β-catenin signalling pathway, causing myocyte 
instability and death and replacement of the myocardium by fibrous fatty tissue. 
This is, to our knowledge, the first report of a variation in CDH2 associated with 
cardiomyopathy in humans. Although the frequency of variants in this gene is small (one 
family), the phenotype of individuals with CDH2 variants appears to be severe, highlighting 
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the importance of including this gene in routine genetic screening of ARVC patients. 
Although CDH2 was included in a candidate gene screen of 13 ARVC patients by Campuzano 
and colleagues, no disease-causing variants were detected.115 As the evidence implicating 
this gene in the development of ARVC is limited to one family, we performed further 
experiments to determine if this gene plays a role in disease pathogenesis in other ARVC 
families (Chapter 5). 
 
4.7. Conclusion 
We identified the novel CDH2 c.686A>C (p.Q229P) variant as a disease-associated variant in 
the ACM2 family, which is likely to play a causal role in the development of ARVC. Our 
research suggests that CDH2 may be a novel candidate gene not only for ARVC but for 




SCREENING OF CDH2 IN AN ARVC COHORT 
 
5.1. Introduction 
Exome sequencing of the ACM2 family with autosomal dominant ARVC identified a putative 
disease-causing variant in a possibly new ARVC gene i.e. CDH2 c.686A>C (p.Q229P) (Chapter 
4). CDH2 encodes the N-cadherin protein which is known to play a role in cell adhesion106, 
similar to the desmosomal genes which have been widely implicated in ARVC. Mouse 
models have demonstrated that deletion of CDH2 causes embryonic lethality due to a 
cardiac defect110, while a cardiac-specific knockout model displays disorganisation of the 
intercalated disc structure106, indicating the importance of this gene in cardiac structure and 
function. As the CDH2 variant was detected in the ACM2 family, it is possible that this 
variant may cause ARVC in other individuals. We therefore screened the rest of our ARVC 
cohort for possible disease-associated variants in this gene. 
 
5.2. Objective 
The objective of this study was to screen the ARVC cohort for possible disease-associated 
variants in the CDH2 gene 
 
5.3. Specific aim 




Patient and control samples were obtained as described previously (section 2.5.1.). DNA 
isolation was performed as previously described (section 2.5.2.). HRM analysis was 
performed as described in section 2.5.4. The primers used for the combined real-time PCR 
and HRM of CDH2 are shown in Table 5.1; the reagents are shown in Table 5.2 and the 
reaction conditions in Table 5.3. 
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Purification and sequencing of HRM products was performed as described in section 2.5.5., 
and population screens were performed as described in section 2.5.6. The methods used for 




Table 5.1: Primers for the PCR and HRM of the CDH2 gene 
 
NAME SEQUENCE LENGTH (BP) %GC Tm (°C) PRODUCT SIZE 
CDH2_Exon1_F ATC AGC TCG CTC TCC ATT G 19 52.6 54.8 
481 
CDH2_Exon1_R AGG AAA GGC GCG AGA GAC CTA C 22 59.1 60.8 
CDH2_Exon2_F GCT TTA TGC CAA GTG GAA TG 20 45 52.1 
323 
CDH2_Exon2_R AGT CTC ATC ATA GTG ATT GTG  21 38.1 49.5 
CDH2_Exon3_F ACT TCT GTG TTT CAT GCT AC 20 40 50.3 
416 
CDH2_Exon3_R TTA GTT CAA ACT GTA TAA AGC TG 23 30.4 48.8 
CDH2_Exon4_F ACT GTG ATT CCT ATG CTT TCA G 22 40.9 52.6 
402 
CDH2_Exon4_R GAG GCT TTC TAC AAC ACT AC 20 45 50.3 
CDH2_Exon5_F AGG GCA TGA AGT GTG ATG TG 20 50 55.3 
322 
CDH2_Exon5_R CAG ACT GAT ATA AGA GGC AAT G 22 40.9 50.6 
CDH2_Exon6_F ATG ATG TAT TTA TCT TCT CAC AGA C 25 32 50.6 
506 
CDH2_Exon6_R CAA CTA AAG CAG AAC GAA AGG 21 42.9 51.9 
CDH2_Exon7_F CTA TTT TGG GGT CCC TGG AAT G 22 50 55.6 
358 
CDH2_Exon7_R GAA AAC GAT TAG CAT TTG AAT AAC  24 29.2 49.2 
CDH2_Exon8_F GAA TGA TGC CAT GCT CTC CTT G 22 50 56.2 
384 
CDH2_Exon8_R GAA ATG TCC GAG TTA GCA GCC  21 52.4 56 
CDH2_Exon9_F GGT GTG GTC ATC AAG ACA AG 20 50 53.4 
421 
CDH2_Exon9_R AAC AGT AAG ATA TAA CCT CCC AG  23 39.1 51.5 
CDH2_Exon10.1_F TTT CCA GAA ACT TGA GAG GAA C 22 40.9 52.7 
415 
CDH2_Exon10.1_R CAC TAC AAA CAG CAT TTC ATA CC 23 39.1 52.2 
CDH2_Exon10.2_F TGT CTG TTA CAG TTA TTG AC 20 35 47.2 
455 
CDH2_Exon10.2_R TGT TTG GCA TAA AGG CAC  18 44.4 50.9 
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Table 5.1: Primers for the PCR and HRM of the CDH2 gene (continued) 
 
NAME SEQUENCE LENGTH (BP) %GC Tm (°C) PRODUCT SIZE 
CDH2_Exon11_F TAT GTC CAG CCA TCA TCT ACA G 22 45.5 53.8 
445 
CDH2_Exon11_R TGC AAA GAC AGT GAA GGA TGT TC 23 43.5 55.6 
CDH2_Exon12_F TTT CAC CAT AAT TGA GGC TC 20 40 50.2 
363 
CDH2_Exon12_R TCA TGC CAG GCT TCA AAA TC 20 45 53.6 
CDH2_Exon13_F ACA TCC TGA ACA ATG CTA TGT G 22 40.9 53.1 
433 
CDH2_Exon13_R GGA AAT GCT GAA AGG TCA AAG  21 42.9 52.2 
CDH2_Exon14_F ATG TGA GGC CAG AAA TAG ATA G 22 40.9 51.8 
366 
CDH2_Exon14_R TGA TGT ATT AAC ACT TCC CAC  21 38.1 49.9 
CDH2_Exon15_F TTC CTC ATT TCT ATG TGT TCT G 22 36.4 50.2 
354 
CDH2_Exon15_R TAG GCC ACA AAT TGC TTG GAA TAC 24 41.7 55.8 
CDH2_Exon16_F TCA TTA GGA TCT GCT TGT GG 20 45 52 
411 










Table 5.2: Reagents for the PCR and HRM of the variants of interest 
REAGENT (STOCK CONCENTRATION) 
FINAL CONCENTRATION / VOLUME PER 
REACTION 
Forward Primer (20 µM) 0.8 µM / 0.5 µl 
Reverse Primer (20 µM) 0.8 µM / 0.5 µl 
dNTPs (20 µM) (Bioline ) 0.8 µM / 1 µl 
GoTaq Polymerase (5U/ ul ) (Promega) 0.5 U / 0.1 µl 
GoTaq FlexiBuffer (5X) (Promega) 1 X / 5 µl 
MgCl2 (25 mM) (Promega) 1.5 mM / 3 µl 
EvaGreen dye (Anatech) 1X / 1 µl 
DNA 200 ng 
FINAL REACTION VOLUME 25 µl 
 










*CDH2 Exons 2, 4 and 7 were amplified at an annealing temperature of 50°C while all other 





5.5.1. Sample characteristics 
Between January 2004 and September 2015, 85 unrelated individuals diagnosed with 
definite (45), borderline (19) and possible (21) ARVC were recruited for molecular genetic 
analysis (Table 5.4). The majority of these patients were male (65.9%), while the average 
age of disease onset for this cohort was 37 (±15.2) years. The ethnic origin of these 85 index 
cases was predominantly Caucasian (50.6%). Palpitations were the most frequent 
presenting symptom (72.9%), followed by dizziness (58.8%), chest pain/discomfort (36.5%) 
and syncope (32.9%). 
 
CONDITION TEMPERATURE (TIME) 




95°C – 5 seconds 
                    *55°C – 10 seconds      50 cycles 
72°C – 10 seconds 
High Resolution Melt 




Table 5.4: Clinical characteristics of the ARVC cohort 
CHARACTERISTIC VALUE % 
NO. OF PATIENTS 85 100 
GENDER 
  
Male 56 65.9 
Female 29 34.1 
AVERAGE AGE IN YEARS (±SD) 46 (±15.7) 
 




Black 6 7.1 
Mixed ancestry 19 22.4 
Caucasian 43 50.6 
Indian 3 3.5 
Not recorded 14 16.5 
PRESENTING SYMPTOMS 
  
Palpitations 62 72.9 
Dizziness 50 58.8 
Chest pain/discomfort 31 36.5 
Syncope 28 32.9 
Dyspnoea 25 29.4 
Sudden cardiac death 6 7.1 
Asymptomatic 3 3.5 
HISTORY OF FAMILIAL DISEASE 17 20.0 
DIAGNOSIS 
  
Definite 45 52.9 
Borderline 19 22.4 
Possible 21 24.7 






5.5.2. CDH2 screening 
We screened a cohort of 85 ARVC patients for variants in the CDH2 gene by high resolution 
melt analysis and Sanger sequencing.  A cohort of 200 ethnically matched control 
chromosomes was screened for all variants of interest. We detected a novel CDH2 
c.1219G>A (p.D407N) variant in ACM11.2, an individual with severe ARVC. No other variants 
of interest were detected. 
 
5.5.2.1. CDH2 c.1219G>A (p.D407N) 
We detected the c.1219G>A (p.D407N) variant in patient ACM11.2 (Figure 5.1). This variant 
was absent in the South African Caucasian background population (as determined by the 
population screen); it was also absent in the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/), NCBI dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and 
Exome Aggregation Consortium (ExAC) browser (http://exac.broadinstitute.org/) databases, 
but was reported in the 1000Genomes database 
(http://browser.1000genomes.org/index.html) in reference to its presence in the COSMIC 
database of cancerous tissue variants (minor allele frequency (MAF) < 0.01%), but has not 
directly been associated with any disease to date. It was predicted to be disease-causing by 
MutationTaster (Disease-causing – 0.999), Polyphen-2 (Probably damaging – 1.00) and 
MutationAssessor (Disease-causing – 4.225) tools while it was predicted to be tolerated by 
the Align GVGD (Class C15) and SIFT (0.12) tools. Bioinformatic tools Mfold and RNAFold 
predicted that this variant would alter CDH2 mRNA secondary structure (Figure 5.3). 
This variant was not found in individual ACM11.1, the unaffected mother of ACM11.2, 
indicating that the variant was either (1) inherited from the proband’s father or (2) a de 
novo variant which arose in ACM11.2 (Figure 5.2). ACM11.2 was diagnosed with severe 
ARVC at 15 years of age. According to the 2010 ARVC Task Force criteria, he fulfils major 
criteria for depolarisation abnormalities (TWI V1-V6), an epsilon wave and structural cardiac 
changes. He also fulfils minor criteria for late potentials and arrhythmia, and also displayed 













Figure 5.1: Identification and conservation of the CDH2 c.1219G>A (p.D407N) variant. (A) 







Figure 5.2: ACM11 family pedigree indicating segregation of the CDH2 c.1219G>A variant 
H. sapiens          394  VDIIVANLTVTDKDQPHTPAWNAV 417 
P. troglodytes  394  VDIIVANLTVTDKDQPHTPAWNA  416 
M. mulatta     377  VDVIVANLTVTDKDQPHTPAWNA  399 
F. catus      341        ANLTVTDKDQPHTPAWNA  358 
M. musculus     394  VDVIVANLTVTDKDQPHTPAWNA  416 
G. gallus     399  VDVIVANLTVTDKDQPHTPA  418 
D. rerio      381  VNVIVTNLTVTDKDEPGTPAWNA  403 








         
              
 
Figure 5.3: Mfold and RNAfold predictions for the CDH2 c.1219G>A variant. (A) Mfold wild 
type structure; (B) Mfold mutant structure; (C) RNAfold wild type structure; (D) RNAfold 
wild type structure 
 
Based on the fact that this variant (1) was absent from all control populations, (2) alters a 
conserved amino acid and (3) is bioinformatically predicted to be deleterious, this variant is 





5.5.2.2. Other CDH2 variants 
We have detected many common variations in CDH2 in our ARVC cohort which had 
previously been found in individuals from the 1000Genomes project. We did not detect any 




Based on genetic and bioinformatic evidence to date, the most likely disease-causing variant 
in the ACM2 family appears to be the CDH2 c.686A>C (p.Q229P) variant (Figure 5.4). This 
variant segregates with disease, is absent in the control population and control databases 
and is bioinformatically predicted to have a deleterious effect on the function of CDH2. We 
therefore screened a cohort of 85 ARVC patients for variants in the CDH2 gene and detected 
the possibly pathogenic c.1219G>A (p.D407N) variant in ACM11.2 (Figure 5.4). 
The CDH2 gene encodes the N-cadherin protein, which is a member of the cadherin 
superfamily of predominantly calcium-dependent cell adhesion proteins.107 As discussed in 
chapter 4, multiple studies have shown the importance of CDH2 in cell adhesion. N-cadherin 
is comprised of five extracellular cadherin repeats, a transmembrane region and a highly 
conserved cytoplasmic tail.108 The cadherin repeats are vital for the adhesive function of N-
cadherin.  Calcium ions bind to each cadherin repeat to ensure correct protein folding and 
confer rigidity to the extracellular domain. Multiple cadherin domains form Ca2+-dependent 
rod-like structures with conserved Ca2+-binding pockets at the inter-domain region.109 The 
p.Q229P variant is located in cadherin repeat 1 while the p.D407N variant is located in 
cadherin repeat 3 (Figure 5.4). It is therefore plausible that these variants in the cadherin 
repeat domains could affect the adhesive function of the N-cadherin protein. 
CDH2 is known to play a vital role in the maintenance of intercalated disc structure106, and is 
also known to be directly involved with the Wnt/β-catenin and hippo signalling pathways.33 
Desmosomal proteins that have the same biological functions have been widely implicated 
in ARVC, making CDH2 a strong candidate for playing a causal role in this disease. It is 
therefore plausible that variants in CDH2 could lead to the development of ARVC by 
disruption of the intercalated disc structure and modulation of the Wnt/β-catenin signalling 
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pathway, causing myocyte instability, myocyte death and replacement of the myocardium 




Figure 5.4: Position of detected pathogenic variants in the CDH2 protein 
 
As discussed in chapter 4, several CDH2 knockout mouse models have been described. The 
first is a homozygous Cdh2 knockout mouse model; the mice died in the embryonic stage 
due to a severe cardiac defect, indicating the importance of Cdh2 in cardiac development 
and function.110 The second is a heterozygous Cdh2 knockout mouse model which exhibited 
a reduction in Connexin-43 plaque size in the myocardium as well as increased susceptibility 
to arrhythmias, showing that N-cadherin influences the function of gap junctions.114 This 
suggests that disruption of one copy of Cdh2 (as in the case of a heterozygous variant or 
knockout), could lead to an arrhythmic phenotype, which is characteristic of ARVC. The third 
model is mice with induced cardiac-specific deletion of Cdh2 displayed dissolution of the 
intercalated disc structure including desmosomes and adherens junctions106, a similar 
observation to what is observed in patients with ARVC. These mouse models also had 
dilated cardiomyopathy and the abrupt onset of ventricular tachycardia, indicating that the 
deaths were arrhythmic in nature.106 
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There is consequently overwhelming evidence that disruption of Cdh2 in rodent models 
leads to a cardiac phenotype – specifically, an ARVC phenotype. However, mouse models 
examining the effects of specific CDH2 variants have not been described, as disease-causing 
variants in this gene have not previously been reported. 
As discussed in chapter 4, this is, to our knowledge, the first report of variants in CDH2 
associated with human disease. The frequency of CDH2 variants in our ARVC cohort is 2/85 
(2.4%). Individuals with CDH2 variants appear to have a severe ARVC phenotype, 
highlighting the importance of including this gene in routine genetic screening of ARVC 
patients. 
There is strong evidence that CDH2 may be a novel causal gene for ARVC based on (1) 
segregation of CDH2 variants with disease in the affected members of the ACM2 family, (2) 
absence of these variants in normal control populations, (3) alteration of conserved amino 
acids by these variants, (4) biological plausibility based on gene function, (5) bioinformatic 
predictions of pathogenicity of the variants, and (6) evidence from animal models that 
disruption of CDH2 leads to an ARVC phenotype.  
5.7. Conclusion 
We detected pathogenic CDH2 variants in two unrelated probands with ARVC (ACM2 and 
ACM11), implicating CDH2 in the pathogenesis of ARVC. This is the first report of CDH2 
variants implicated in heart disease, and emphasises the need to include CDH2 in genetic 
screening of ARVC patients.  
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CHAPTER 6 
SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
6.1. Summary of findings 
The main objective of this study was to identify the genetic cause of arrhythmogenic right 
ventricular cardiomyopathy (ARVC) in the ACM2 family with autosomal dominant disease. 
6.1.1. Candidate gene screening: PLN 
We used the candidate gene screening approach and screened the ACM2 family for variants 
in PLN, but did not detect any disease-causing variants. Simultaneously, we screened a 
cohort of 85 other ARVC patients as well as patients with DCM, HCM or PPCM for variants in 
PLN and detected the reported pathogenic PLN c.25C>T (p.R9C) variant in the DCM320 
family. No other disease-causing PLN variants were detected. 
6.1.2. CNV analysis 
We then performed whole genome copy number variation (CNV) analysis to search for large 
changes in DNA copy number which could be associated with ARVC, but detected no 
deleterious CNVs. There have been limited reports of CNVs in inherited cardiomyopathies to 
date. These CNVs reported as associated with cardiomyopathy are limited to deletions in 
BAG3116 and LMNA117 in individuals with DCM, deletions in PKP292,93 and DSP94 in individuals 
with ARVC and a duplication in MYBPC3118 in individuals with HCM. Given the rarity of 
pathogenic CNVs in cardiomyopathy, it is not surprising that we failed to detect disease-
causing CNVs in the ACM2 family. 
6.1.3. Exome sequencing 
We performed exome sequencing for two affected members of the ACM2 family. Family 
screening, population screening and bioinformatic analysis pinpointed the novel deleterious 
CDH2 c.686A>C (p.Q229P) variant as the disease-associated variant in the ACM2 family. 
97 
 
6.1.4. Candidate gene screening: CDH2 
We screened 85 ARVC patients for variants in CDH2, and identified the deleterious CDH2 
c.1219G>A (p.D407N) in the ACM11 family. This provides additional evidence for the role of 
CDH2 in the pathogenesis of ARVC.  
 
6.2. Conclusions 
There have been many reports of genetic factors associated with cardiomyopathy to date. In 
ARVC, the focus was initially predominantly on the desmosomal genes, which are now 
known to be responsible for 30-50% of ARVC cases. More recently, other genes with diverse 
functions have been implicated in this disease. However, the amount of evidence for the 
involvement of these genes in ARVC is varied, and it has become increasingly challenging to 
prove the pathogenicity of variants thought to be deleterious. 
 
6.2.1. New sequencing methods facilitate faster variant identification 
Early genetic studies, including those involving cardiomyopathy patients, adopted a 
candidate gene approach for variant identification. Genes of interest were selected based 
on linkage information or current knowledge about gene function, and the sequencing of 
these genes was performed by the Sanger sequencing method. Newer methods allow the 
simultaneous targeting of multiple genes, facilitating a more efficient and less time-
consuming approach to pinpointing disease-causing variants. These methods include 
targeted sequencing of multiple genes of interest, exome sequencing and whole genome 
sequencing with various next generation sequencing platforms. 
 
6.2.2. Importance of stringent variant classification criteria 
In recent years, the number of studies reporting genetic variants in patients with 
cardiomyopathy has increased dramatically. The advent of next generation sequencing has 
led to faster identification of variants in patients with various diseases, including 
cardiomyopathy. This increase in the identification of variants against the background of 
large amounts of other genetic information from next generation sequencing experiments 
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has made it more challenging to separate truly causal variants from variants that are 
associated with disease but are not necessarily pathogenic. 
The key to ensuring correct variant classification is a stringent set of criteria which will allow 
unbiased assessment of any variant and provides the most accurate determination of 
variant pathogenicity. Using more recent classification criteria, many variants previously 
deemed pathogenic have been reclassified as variants of unknown significance, as the 
original evidence provided for causality is no longer substantial according to more recent 
criteria. In our study, we have used a very stringent set of criteria for variant classification, 
and variants which we have classified as pathogenic have strong evidence for causality or 
association with disease. 
 
6.2.3. Importance of accurate phenotyping information 
During the course of this project, the importance of current and comprehensive phenotype 
information was highlighted. Correct classification of patients according to the most recent 
ARVC Task Force Criteria and based on thorough examination was of great importance in 
pinpointing the causal variant in the ACM2 family. Uncertainty about the classification of 
patients due to incomplete patient information causes difficulty when attempting to 
establish genotype-phenotype relationships. Much care should be taken to ensure rigorous 
and unbiased phenotyping of patients before inclusion in a genetic study. 
 
6.2.4. The ACM2 family 
There has been much work performed on the ACM2 family to date, spanning multiple 
experiments over a number of years, but no disease-causing variant had been found. In this 
study, we identified the pathogenic CDH2 c.686A>C (p.Q229P) variant by exome sequencing. 
CDH2 screening of a cohort of 85 other ARVC probands revealed the c.1219G>A (p.D407N) 
variant, providing further evidence of the contribution of CDH2 variants to the pathogenesis 
of ARVC. This is the first report of CDH2 variants associated with human disease, and 
establishes this gene as a novel cause of ARVC. 
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Previous studies on African cardiomyopathy patients implicated the PKP2 gene in ARVC.13,22 
Variants in PKP2 included the c.1162C>T (p.R388W) founder variant present in many South 
African individuals of European descent.13,22 The identification of CDH2 as a new ARVC-
causing gene in the South Africans with cardiomyopathy sets the stage for inclusion of CDH2 
in routine cardiomyopathy screening both locally and internationally. 
6.2.5. Limitations 
The different techniques utilised in this study have a number of limitations. The candidate 
gene screening approach used in chapter 2 is limited in scope as only the PLN gene is 
evaluated. The copy number variant screening approach used in chapter 3 evaluates large 
genetic variations (>1kb) and is unable to detect smaller genetic changes. The performance 
of an exome sequencing experiment has addressed the limitations of these techniques. 
However, exome sequencing does not cover the intergenic and the majority of intronic 
regions of the genome, but as the inheritance pattern of the ACM2 family is autosomal 
dominant, it is most likely that the disease-causing variant would be located in the exonic 
region as has been found in this study. 
Another limitation of this study arises with the use of bioinformatic tools to predict the 
effect of variants on gene function and their consequent likelihood of playing a causal role in 
disease development. These tools predict the effect of genetic variants based on existing 
information about the structure, function and conservation of the affected genes, 
transcripts and proteins.119 However, as these tools determine variant effect severity in 
different ways, use of more than one tool is recommended to obtain an overall predictive 
result and ensure optimal sensitivity and specificity, as we have done in this study. Results 
obtained with these tools should however be interpreted with caution and require 
validation with functional experiments. 
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6.2.6. Future directions 
There are several lines of investigation that are required to establish the significance of 
variants in the CDH2 gene in cardiomyopathy. First, a variant screening study of the CDH2 
gene is required in a large series of cases and families of ARVC and other forms of 
cardiomyopathy. These studies will serve to confirm the causal role of CDH2 variants in 
cardiomyopathy and determine the prevalence of variants in this gene in patients with 
cardiomyopathy. Second, studies of the expression of the desmosomal proteins in heart 
tissues of affected and unaffected individuals will be informative in establishing the role of 
variants in CDH2 in human disease.120 In addition to studies of the expression of normal and 
mutant protein in human tissues, in vitro studies of the interaction of CDH2 with other 
proteins using systems such as the yeast-2-hybrid system can be conducted. Other 
experiments to assess the functional impact of the CDH2 c.686A>C and c.1219G>A variants 
may involve the use of animal models and induced pluripotent stem cells.121  
Although mouse models with deletions of one or both copies of CDH2, as well as cardiac-
specific knockouts, have been established106,110,114 and have demonstrated that a decrease 
in CDH2 levels leads to an ARVC-like phenotype, there are no reported studies assessing the 
functional impact of CDH2 point variants. Studies that will establish the mechanism of 
disease caused by CDH2 variants will elucidate the molecular pathways involved in the 
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APPENDICES 
Appendix 1: ARVC study patient consent form 
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Appendix 2: Solutions 
2.1. 1X TBE Buffer 
10.8 g Tris (Promega) 
5.5 g Boric Acid (Riedel-de Haën) 
7.4 g EDTA (Promega) 
Made up to 1 litre with dH2O 
2.2. 1% Agarose Gel 
1 g Agarose (Roche) 
Volume made up by 100 ml 1X TBE Buffer 
2.3. 2% Agarose Gel 
2 g Agarose (Roche) 
Volume made up by 100 ml 1X TBE Buffer 
